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ABSTRACT 
Metastatic dissemination of breast cancer cells represents a significant 
clinical obstacle to curative therapy. While some progress has been made in the 
understanding of metastasis, the detailed molecular mechanisms that define the 
various stages of the process remain elusive. A major rate limiting step in 
metastasis is the loss of function of metastasis suppressor genes which block a 
cascade of crucial steps including the loss of adhesion of primary tumor cells, 
intravasation into the blood and lymphatics with subsequent extravasation at 
distant sites, and the formation of new colonies. Our examination of gene 
expression profiles from a breast cancer model system consisting of cell lines 
with the same genetic lineage representing the benign, carcinoma in situ and the 
metastatic stages led to the identification of a candidate metastasis suppressor 
gene, serum deprivation response (SDPR). We observed that stable SDPR over-
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expression in highly metastatic breast cancer model cell lines significantly 
suppressed metastatic nodule formation in NOD/SCID mice. Furthermore, meta-
analysis of pre-existing gene expression data suggests that the loss of SDPR 
expression significantly correlated with relapse of breast cancer in patients who 
underwent therapy. We found that the mechanism of SDPR function involves 
activation of the p53 pathway and inhibition of ERK and NF-κB signaling 
pathways. SDPR increased the apoptotic population, hindered growth in 3D cell 
culture and impaired migration. Moreover, SDPR was suppressed by promoter 
DNA methylation in metastatic cell line models and its expression was restored 
by 5-aza-2'-deoxycytidine treatment. Together, our results reveal that SDPR is a 
novel metastasis suppressor gene with potential value as a target for future 
therapeutic applications. 
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CHAPTER 1: METASTASIS 
BACKGROUND 
Metastasis is the cause of almost all cancer related deaths. It is an 
extremely complex, multistep process defined as the spreading of cancer cells 
from their primary site to distant tissues. Once metastasis occurs it causes 
catastrophic damage to the critical organs, which is ultimately detrimental for the 
patients. Collective efforts of many scientists have revealed the underlying 
molecular mechanisms of metastasis by a considerable extent but there is still a 
colossal job to be undertaken by researchers to solve this life-threatening health 
problem.  
In this chapter, metastasis is explained by focusing on underlying 
molecular pathways. I define the steps that a cancer cell needs to climb in order 
to metastasize and mention the significant molecular actors aberrantly regulated 
during this process.  First, I discuss how these molecules are deregulated in 
cancer cells in order to circumvent natural barriers against metastasis. Then, I 
give a molecular explanation on why some cancer types metastasize to certain 
organs. Lastly, I look into metastasis suppressor genes, their roles in cellular 
pathways and how they are repressed in cancer.   
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Figure 1: The metastatic cascade. Metastasis is a multistep progress which 
consists of intravasation, extravasation and colonization. 
Metastasis as a Complex, Multistep Event: 
The spreading of cancer cells to distant tissues from their primary site is 
called metastasis. Although it is an extremely complex event, metastasis (or the 
metastatic cascade, named due to its multistep nature) can be analyzed in three 
main steps: intravasation, extravasation and colonization (1, 2) (Fig. 1).  
Metastasis begins with formation of an invasive tumor.  As its name 
implies, an invasive tumor has the ability to invade neighboring tissues. During 
this process many cancer cells can enter the blood stream or lymphatic vessels 
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by degrading the basement membrane and migrating through endothelial cells 
(3, 4). This first step in the metastatic cascade, entrance of cancer cells into 
blood or lymphatic vessels is referred to as intravasation. Many of the cells, that 
successfully intravasate, die due to a specific type of apoptosis called anoikis (2, 
4-6). Anoikis is initiated by the loss of cells’ supportive contacts to the 
extracellular matrix and to their neighboring cells. Yet another group of 
intravasated cells die because of the sheer mechanical forces they encounter in 
the circulation (2-4). Still, some survive and stick to capillaries in distant tissues. 
These stuck cancer cells may enter quiescence and live in a dormant phase or 
may migrate through endothelial cells and exit from capillaries into the tissue. 
This step in metastasis is called extravasation. An extravasated cancer cell is in 
a complete “alien world” compared to its tissue of origin. It is exposed to different 
sets of extracellular apoptotic signals and growth factors. Here, it needs to “learn” 
how to cope with a new set of death signals and how to benefit from the new set 
of growth factors (7). Once a cancer cell can master the new microenvironment, 
it can start to divide and form a colony. This final step of the metastatic cascade 
is called colonization and it is the rate limiting step of metastasis. Compared to 
colonization, intravasation and extravasation steps are “easier” for a cancer cell 
to be successful at. A cell in an invasive tumor may enter and exit circulatory 
system because of already accumulated mutations at the primary site. However, 
colonization of a distant tissue requires another distinct set of mutations and 
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epigenetic changes that equip or prime the cell to be successful in a completely 
different tissue.  
Only a tiny fraction of cells in primary the tumor can successfully climb all 
these steps of the metastatic cascade and gain the ability to colonize (2). In the 
next sections, I look into the molecular details of these three main steps of 
metastasis. 
Intravasation: 
When a benign in situ carcinoma turns into an invasive carcinoma, the 
cancer cells undergo a transformation highlighted by their ability to alter their 
microenvironment (Fig. 2). They recruit stromal cells to “nurse” themselves, 
initiate formation of blood vessels by attracting endothelial cells and start to 
degrade the basement membrane and extracellular matrix which may otherwise 
block their growth (4). Elucidating the underlying molecular mechanisms of these 
changes has been crucial to understanding how an invasive tumor enters the 
metastasic cascade.  
One of the major changes occurs on the surface of cancer cells. Adhesion 
to neighboring cells is very critical in defining the architecture of epithelial tissues.  
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Figure 2: Intravasation. During the intravasation stage, a malignant cell can 
manipulate the microenvironment around it. VEGF secreted from cancer cell can 
recruit and activate endothelial cells and induce angiogenesis. Moreover, 
abnormal VEGF activity makes endothelial cell layer “leaky”. Similarly, CSF1 
secreted from cancer cells recruits macrophages which are critical for 
extracellular matrix remodeling. Recruited macrophages secrete EGF and 
cathepsins. Cathepsins can cleave membrane proteins such as E-cadherin that 
in turn disturb cell to cell interactions. This results in liberation of malignant cells 
from neighboring cells. EGF can act as a chemoattractant and can also initiate 
migration of cancer cell, facilitating intravasation.      
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Interactions with neighboring cells give clues (signals) to a cell about when to 
divide, when to migrate and how to function. Cadherins, a family of 
transmembrane proteins, play important roles in these cell to cell interactions and 
downstream signaling. Cancer cells alter their expression of cadherins according 
to their advantage during metastasis (8). E-cadherin (CDH1) is mainly expressed 
in epithelial cells but is often down-regulated  in invasive cancer cells. Loss of E-
cadherin leads to loss of cell to cell adhesions, resulting in a more migratory 
phenotype, which facilitates intravasation (3, 9).  
Members of the transforming growth factor-beta (TGFβ) signaling pathway 
are among commonly altered proteins by cancer cells (10). TGFβ receptors 
recognize extracellular ligands and activate SMAD proteins to transcriptionally 
regulate a large set of genes which have roles in a wide array of cellular events 
including differentiation and migration (9-11). Activation of the TGFβ pathway 
results in transcriptional activation of master regulators such as Snail, Slug and 
Twist (9, 12, 13). This results in loss of epithelial cell markers such as E-
cadherin, γ-catenin and gain of mesenchymal markers such as N-cadherin 
(CDH2), vimentin and alpha smooth muscle actin. This de-differentiation is called 
epithelial to mesenchymal transition (EMT). Cancer cells which have undergone 
EMT acquire a migratory phenotype (3, 12) and this enhances tumor cell 
invasion and thereby intravasation.    
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Tumor cells require the formation of blood vessels in order to sustain their 
growth. Cancer cells can meet this requirement by secreting vascular endothelial 
growth factor (VEGF) protein at very high levels (2, 14). VEGF act as chemo-
attractant for endothelial cells and causes their migration, proliferation and 
differentiation (4, 14). This leads to formation of blood vessels that can support 
the continued growth of the tumor. Since the level of VEGF is chronically high 
and lacks a directive gradient, it results in formation of a chaotic network of 
vessels. In this environment, endothelial cells cannot form proper vessels, where 
each of them attaches to one another in an orderly structure. Instead, they form 
“leaky” blood vessels providing cancer cells with more opportunities to enter the 
circulatory system (14). 
One of the hallmarks of invasive tumors is their ability to degrade the 
basement membrane and surrounding extracellular matrix. The basement 
membrane defines and supports epithelial cell layers in normal tissues and it 
blocks the unchecked growth of tumor cells. The extracellular matrix creates a 
three dimensional environment for cells to function and regulates their growth. 
Cancer cells circumvent the unfavorable effects of the basement membrane and 
extracellular matrix by expressing metalloproteases [MMPs] such as MMP2 and 
MMP9 (4, 13, 15, 16). Degradation of these structures by MMPs removes the 
physical barriers that confront tumor cells and, moreover, liberates sequestered 
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growth factors. This combination acts to fuel cancer cell growth and aids in 
intravasation. 
Another significant family of proteins on the surface of cancer cells is the 
integrin receptor family. Integrins are transmembrane proteins that function in cell 
to matrix interactions. Overexpression of certain integrins by tumor cells 
facilitates their migration throught the extracellular matrix (17, 18). Integrins αvβ3 
and α3β1 bind to ligands in extracellular matrix such as collogen, fibronectin and 
laminin which provides “grip” for cancer cell migration (3, 18). By creating a 
complex with ErbB2 receptor (also known as HER2), integrin β4 can also 
increase the invasiveness of cancer cells (18, 19). The ability of invasive cancer 
cells to overexpress integrins can, in many cases, foster migration, which in turn 
enables intravasation.  
In a tumor, cancer cells are far from being the only residents. Cancer cells 
recruit many other cell types (called “tumor associated” cell types) to create the 
optimum settings for their growth. Tumor associated macrophages (TAMs) are 
among these cells. They are recruited to the tumor by the expression of 
cytokines such as interleukins-8 (IL-8), -6 (IL-6) and colony stimulating factor-1 
(CSF1) (4, 16, 20, 21). TAMs can then recruit endothelial cells to form blood 
vessels. Blood vessel formation is required to sustain tumor growth and provides 
more alleyways for cancer cells to escape from the primary site (21). Additionally, 
TAMs secrete epidermal growth factor (EGF) which initiates tumor cell migration 
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and CSF1 production in tumor cells (4). CSF1 production, in turn, recruits more 
TAMs to complete the “cycle”. During this process, cancer cells migrate towards 
the source of the EGF and TAMs migrate towards source of CSF1. The 
directional migration of cancer cells (cell streaming), along with the aid of TAMs 
may end with the entrance of cancer cell to the blood stream. TAMs also secrete 
cysteine cathepsins, proteases whose targets include surface proteins (4, 22, 
23). One of the most interesting targets of capthepsins is E-cadherin. Cleavage 
of E-cadherin on the cancer cell surface disrupts cell to cell junctions and 
releases cancer cells that are free to migrate (23). 
The beginning of the metastatic cascade is marked by entrance of cancer 
cells into blood or lymphatic vessels. This first step, intravasation, requires many 
alterations at molecular level involving diverse cellular functions. To intravasate, 
a cancer cell must detach from neighboring cells (loss of E-cad expression, 
cathepsin activity), recruit endothelial cells to form the escape routes (VEGF 
expression and TAMs recruitment), degrade the basement membrane and 
extracellular matrix to migrate through them (secretion of MMPs and expression 
of integrins) and attract TAMs to guide them during migration (secretion of 
cytokines). 
 
Extravasation: 
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Extravasation is defined as the exit of circulating cancer cells from a blood 
or lymphatic vessel into a distant tissue. A successfully extravasated cell must 
have survived in circulation, docked to the vessel wall, migrated through 
endothelial cells and entered into the distant tissue by degrading the basement 
membrane supporting endothelial cells (Fig. 3). In this section, I analyze the 
molecular actors and their respective functions during these events.  
 
Figure 3: Extravasation. Cancer cells which can escape from anoikis following 
intravasation may dock to the vessels walls via weak interaction with selectins on 
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endothelial cells. Integrins on cancer cell membrane can sustain stronger 
interactions to the endothelial cells. Moreover, molecules such as VEGF and 
ANGPTL4 disturbs endothelial cell layer. Together these molecular players 
facilitate migration of cancer cell through endothelial cell layer into distant tissue. 
Once a cancer cell has intravasated, it is in a suspension. This is a 
completely different environment for a carcinoma cell, compared to the solid 
tumor where it used to reside. In a solid tumor, a cancer cell can attach to 
extracellular matrix, neighboring cancer cells or tumor associated cells. These 
interactions present survival signals and a structural framework that supports 
growth of the tumor. Intravasated cancer cells lack all of these support elements. 
Furthermore, they are challenged by an internal pre-programmed mechanism 
that is triggered upon loss of solid connections: anoikis (5).  
Anoikis is a form of apoptosis. A cancer cell adheres to its neighbors and 
the extracellular matrix through membrane proteins such as cadherins and 
integrins. These transmembrane proteins relay survival and anti-apoptotic 
signals. Withdrawal of these signals upon loss of attachment results in automatic 
induction of the apoptotic cascade (2, 24). Bid and Bim are Bcl-2 family proteins 
that act as activators of the apoptotic cascade (5). They bind to Bax and Bak 
proteins and facilitate their insertion to the outer mitochondrial membrane. This 
causes permeabilization of the membrane and release of cytochrome-c protein. 
In the cytoplasm, cytochrome-c binds to Apaf-1. The Apaf-1/cytochrome-c 
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complex, then, activates caspase-9 which initiates the caspase cascade and 
results in mass protein degradation and eventual cell death (5). The main 
advantage of this cascade of interactions for apoptosis is that it presents many 
checkpoints before committing an extremely critical decision: suicide. Cells have 
inhibitors and activators for each of the mentioned steps. As a whole, this gives 
cells a very fine tuned decision mechanism but it also gives a cancer cell many 
possible targets to alter in order to survive. Indeed cancer cells have many 
mutated genes that functions to inhibit apoptosis.    
One of the most attractive targets for cancer cells to block apoptosis is the 
RAS pathway. RAS proteins are GTPases that play pivotal roles in many vital 
signaling pathways and cellular events. Transmembrane receptors we have 
mentioned above such as integrins and growth factor receptors converge on the 
RAS pathway through downstream signaling events. Cancer cells often have 
constitutively active RAS pathways that relay anti-apoptotic/survival signals even 
when they lose their attachment to a solid surrounding (25).  
Active TGFβ signaling and resulting initiation of EMT in cancer cells 
increases the population of cells equipped with stem cell like features (12, 26). 
Cancer stem cells are marked by CD44 overexpression and CD24 repression. 
One of the main advantages CD44+/CD24- cells have is the anchorage 
independent growth. This allows them to survive in circulation without a need for 
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solid attachments after intravasation and represents another pathway that cancer 
cells can manipulate to their benefit during metastasis.  
To continue with their distal growth program, surviving cancer cells need 
to exit the circulatory system. A cancer cell can extravasate upon becoming 
trapped in small capillaries or by actively docking to endothelial cells of larger 
diameter veins. Glycoproteins such as CD44, podocalyxin-like (PODXL), 
carcinoembryonic antigen (CEA) and integrins expressed on the surface of the 
cancer cells are critical for this process (3). CD44 and PODXL are recognized by 
P- and E-selectins on endothelial cells (27-29). These interactions are temporary, 
because physical forces between selectins and glycoproteins are weak, but they 
gain precious time for stronger bonds to occur. More stable attachments take 
place between integrins and their ligands on endothelial cells, intercellular 
adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule 1 (VCAM1) 
(3, 17, 30, 31). Binding of integrins to ICAM and VCAM on the endothelial 
surface provides an opportunity for cancer cells to extravasate. 
Tumor associated platelets are loyal allies of cancer cells during 
extravasation (18, 31). Following intravasation, tumor associated platelets and 
cancer cells can be joined together through “fibrinogen bridges” where both cells 
attach to the same fibrinogen molecule by the integrins on their surface. This 
allows cancer cells to receive survival signals even when they are in circulation 
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and helps them to cope with anoikis. Moreover, platelets assist cancer cells in 
sticking to the endothelial cells and enhances their chance to extravasate.  
Once cancer cells bind to the vessel walls, they start to “claw” their way 
into to the new tissue. Similar sets of proteins used during invasion at primary 
site aid in their infiltration. Secretion of VEGF makes endothelial cells more 
permeabable; integrins let cancer cells attach to the basement membrane 
supporting endothelial cells and initiates migration; MMPs digest basement 
membrane and supporting extracellular matrix to “dig” a tunnel where cancer 
cells migrate further into the tissue. As a result of the collective action of these 
molecules and tumor associated cells, a cancer cell can extravasate successfully 
to a new nest.  
Colonization: 
Even when a cancer cell is successful at extravasation, this does not 
guarantee it will grow in the foreign soil. The vast majority of extravasated cells 
cannot sustain their growth and either die or enter into a quiescence stage. At 
best, it is only around 1 out of 4000 extravasated cells that eventually colonize a 
distant tissue (6). In order to colonize, cancer cells not only have to adapt to their 
new microenvironment but also redesign it. This may take decades for a cancer 
cell to achieve. That is why colonization is the rate limiting step of metastatic 
cascade. A cancer cell needs to find creative solutions to survive and thrive in 
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distant tissues. In this section, I look into molecular mechanism underlying 
colonization.  
Cancer cells undergo EMT in order to facilitate their intravasation and 
extravasation, but this has a major drawback: inhibition of proliferation. Activators 
of EMT such as TGFβ slow down cell division. Therefore, extravasated cells 
revert back to a more epithelial like phenotype through mesenchymal to epithelial 
transition (MET). This is marked by upregulation of epithelial proteins such as E-
cad and CD24 (2, 32). miR-200 is a key regulator of MET and downregulates the 
transcriptional repressors zinc finger E-box-binding homeobox 1 (Zeb1) and 2 
(Zeb2) (2, 12, 32-35). These proteins are responsible for E-cad suppression 
during EMT. Once, E-cad levels reach a certain threshold it can further augment 
MET by inhibiting Snail through sequestering β-catenin and p65 (36). Also, 
extracellular signals received upon arrival to distant tissue such as BMP7 can 
induce MET (12, 37). After a cancer cell has gone through MET and released 
from growth arrest, it may have an opportunity to colonize. 
As stated previously, a cancer cell must learn how to benefit from the 
growth factors and surrounding host cells in the distant tissue in order to 
colonize. Cancer cells which extravasate in bone tissue may sustain their growth 
by expressing C-X-C chemokine receptor 4 (CXCR4) to recognize stromal 
derived factor 1 (SDF1) (38). Moreover, these cancer cells secrete IL-6, IL-11, 
tumor necrosis factor-α (TNF-α), and parathyroid hormone-related protein 
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(PTHRP), which activates resident osteoblast cells to secrete receptor activator 
of nuclear factor kappa-B ligand (RANKL) (4, 39). RANKL promotes the 
differentiation of mature osteoclast. Osteoclasts are responsible for bone matrix 
the degradation during bone remodeling (osteolysis). Degradation of bone matrix 
releases a plethora of growth factors including TGFβ, bone morphogenetic 
proteins (BMPs) and insulin-like growth factor 1 (IGF1). These growth factors 
boost cancer cell growth further and complete a vicious positive feedback loop 
that may eventually result in colonization. 
 A very intriguing hypothesis is that tumor cells may cause remodeling of 
possible site of colonization even before their arrival (2, 7). Cancer cells secrete 
VEGF and lysyl oxidase (LOX) which can be transported to possible distant 
metastatic sites through systemic circulation and initiate remodeling of the 
extracellular matrix (40). Transported VEGF recruits VEGF receptor 1 (VEGFR1) 
expressing bone marrow derived cells (BMDCs) and LOX can directly transform 
the composition of extracellular matrix by crosslinking collagens and elastins. 
Recruited VEGFR1+ BMDCs express MMP9 which further changes the 
architecture of the extracellular matrix and by doing so releases growth factors 
and chemokines sequestered in it (2). The effects of LOX on extracellular matrix 
activate existing fibroblasts and initiate expression of fibronectin. Secreted 
fibronectin can be recognized by integrins on cancer cells to support their growth. 
Distant tissue sites affected by this remodeling are referred to as metastatic 
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niches. Metastatic niches may support the survival of extravasated cells and 
possibly assist in colonization. 
Cancer cells that extravasate successfully and are able to survive initially, 
have to induce angiogenesis in order to colonize the distant tissue. Angiogenic 
factors such as VEGF and FGF are expressed by cancer cells to initiate blood 
vessel formation. VEGF, again, plays a crucial role by recruiting endothelial 
progenitor cells (EPCs) (41). EPCs are required for colonization because they 
support angiogenesis.  
In order to persist at a distant site, cancer cells have to cope with the 
extracellular death signals that may lead to apoptosis. Encountered death signals 
includes Fas ligand (FASL), TNF-α and tumor necrosis factor (ligand) 
superfamily, member 10 (TRAIL) (42). Once recognized by receptors expressed 
on the cell surface, these death signals activate death-inducing signaling 
complex (DISC). Activation of DISC liberates caspase-8 which induces the 
caspase cascade and subsequent apoptosis. Cancer cells can circumvent 
apoptosis by repressing expression of caspase-8, a metastasis suppressor, at 
the transcriptional level through methylation of DNA in the promoter region of the 
gene (43, 44). This makes cancer cells more resistant to extracellular death 
signals and gives them an opportunity to colonize.   
Cancer cells also have to cope with internal blocks that confront 
metastasis -metastasis suppressor genes. Metastasis suppressors are defined 
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as genes that inhibit metastasis but do not have any apparent effects on primary 
tumor (45, 46). These genes, probably, affect colonization since this is the rate-
limiting step where most cancer cells fail. Metastasis suppressors include non-
metastatic cells 1, 2 (NME1, NME 2 –also known as NM23, NM23B), KISS1, 
KAI1 (also known as CD82), mitogen activated protein kinase 4 (MAP2K4) (47-
51). Surprisingly, some of these metastasis suppressor genes converge on the 
RAS pathway (45). As mentioned earlier, the RAS pathway has critical roles in 
apoptosis and cell proliferation. A subtle push towards apoptosis or a hick-up in 
proliferation provoked by the action of metastasis suppressors may make cancer 
cells incompetent at colonization. MicroRNA-31 is another significant metastasis 
suppressor (2). It represses a set of prometastatic genes including integrin α5, 
MMP16 and ras homolog gene family, member A (RhoA) (52). As a result miR-
31 function effectively impairs colonization of cancer cells. A cancer cell has to 
repress these internal blockades, metastasis suppressors, in order to colonize a 
distant tissue.  
Colonization is the stage at which cancer cells are least efficient. The traits 
they have acquired during invasion and intravasation, such as activation of EMT 
program, may work against them at the distant site. Only the cells that have the 
plasticity to transform into an adequate phenotype may have a chance to 
prosper. They have to be equipped with the receptors to benefit from new growth 
factors that are presented to them in the new site. A cancer cell also has to 
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express growth factors, chemokines and proteases that will remodel the 
microenvironment around them into a more hospitable host (expression of 
molecules such as interleukins, VEGF, FGF, MMPs). Moreover, cancer cells 
need to be resistant to both extracellular death signals and the intracellular 
apoptotic program in order to survive and colonize. Having all these favorable 
traits ready even before extravasation is equal to winning the lottery for a cancer 
cell and explains why colonization is the most inefficient and rate-limiting step 
during metastasis.   
Fortunately, the many steps a cancer cell has to climb in order to 
successfully metastasize at a distant tissue are very steep. As demonstrated by 
the complexity of the underlying molecular mechanisms, metastasis is a 
multidimensional, multivariable problem for a cancer cell to solve. The formation 
of metastasis requires a cancer cell to be extremely plastic in order to adapt 
different microenvironments. They need to cope with intrinsic and extrinsic death 
signals and, moreover, they need to educate other cell types to assist them 
during metastasis.  
Organ Specific Metastasis:   
From very early on, it has been realized that certain cancers prefer certain 
target organs to metastasize. Prostate cancer almost exclusively metastasizes to 
the bones; colorectal and pancreatic cancers metastasize to the liver and the 
lungs; whereas breast cancer can metastasize to a wider range of organs 
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including the bones, lungs, liver and brain (2, 16). A straightforward explanation 
for this organ specific metastasis may lie in the anatomy of circulatory system. 
Cancer cells shed from the primary site after intravasation follow the course of 
the blood stream and stick in the capillaries of the organ next in line. Therefore, 
most of the intravasated colorectal cancer cells accumulate in liver tissue while 
most breast cancer cells arrive in the lungs. Still, the anatomy of the circulatory 
system does not give the full explanation of organ specific metastasis and the 
underlying molecular biology seems to play a significant role. In this section, I 
look at the molecular actors and their roles underlying organ-specific metastasis.  
Chemokines are among the most intriguing actors for organ specific 
metastasis. They are relatively small, secreted proteins which can induce 
migration of target cells (21). They function in organogenesis during development 
and during immune responses in adults. Cancer cells expressing chemokine 
receptors can take advantage of these pathways during metastasis. The most 
commonly expressed chemokine receptor in cancer cells is CXCR4 (21, 53). Its 
ligand, SDF1 is expressed in bone marrow, liver, lungs and brain. As a result, 
CXCR4+ cancer cells can actively extravasate to the SDF1 expressing organs 
and cause metastasis. A striking example of chemokine involvement in organ 
specific metastasis comes from different subsets of melanomas (54). Chemokine 
(C-C motif) receptor 9 (CCR9) positive melanoma cells specifically metastasize 
to small intestine because CCR9 recognize chemokine (C-C motif) ligand 25 
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(CCL25) expressed in this tissue (55). However, expression of CCR10 by 
melanoma cells leads to skin metastasis where the CCR10 ligand, CCL27, is 
highly expressed (54, 56). Yet another subset of melanoma cells, expressing 
CCR7, metastasizes to lymph nodes (57). CCR7’s interaction with its ligand 
CCL21 also facilitates lymph node-specific metastasis of lung and gastric 
cancers (58, 59).   
As stated earlier, breast cancer can metastasize to a rather wide range of 
organs including bones, lungs, brain and liver. Each of these metastases has a 
particular set of genes that facilitate organ specificity. A lung metastasis specific 
gene signature of breast cancer includes secreted protein, acidic, cysteine-rich 
(SPARC), interleukin 13 receptor, alpha 2 (IL13RA2), VCAM1 and MMP2 (60). 
These genes have roles in extracellular functions, which suggest that they allow 
breast cancer cells to alter their microenvironment in the lungs. Active TGFβ 
signaling can also facilitate breast cancer metastasis to lungs (61). TGFβ 
signaling induces angiopoietin-like 4 (ANGPTL4) expression by SMAD 
transcriptional factors. In turn, ANGPTL4 assists trans-endothelial migration of 
cancer cells by disturbing cell to cell junctions on the blood vessel walls.  
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 5 (ST6GALNAC5) was 
discovered as a determinant for brain specific metastasis of breast cancer (62). 
ST6GALNAC5 in cooperation with epiregulin (EREG) and prostaglandin-
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endoperoxide synthase 2 (COX2) assists in breast cancer cell adhesion to 
endothelial cells and facilitates migration through the blood-brain barrier.  
Liver specific metastasis of breast cancer cells is marked by expression of 
claudin 2 (CLDN2) (63). CLDN2 is sufficient and necessary for breast cancer 
cells to metastasize to the liver. It increases detectable levels of α2β1 and α5β1 
integrin complexes on cell surface which in turn enhances breast cancer cells 
adhesion to the extracellular matrix components.  
IL-11 expressing breast cancer cells specifically metastasize to bones 
where they initiate a vicious osteolytic cycle (see previous section).  
Bone seems to present an attractive setting for metastasis since many 
different types of cancers can metastasize to this tissue (64). Interestingly, 
though, they do not use a similar molecular machinery to do so. As stated above, 
breast cancer cells express IL-11 and CXCR4 to colonize bone. On the other 
hand, neuroblastoma cells express RANKL or stimulate mesenchymal stem cells 
to synthesize IL-6 which, similar to breast cancer, initiates a detrimental 
osteolytic cycle. Prostate cancer uses yet another strategy to metastasize to 
bone. Instead of activating an osteolytic cycle, they predominantly cause 
aberrant osteoblast proliferation by producing FGF8, TGFβ2 and endothelin 1. 
This leads to excess bone depositions, which serve as rich sources of 
sequestered growth factors. Meanwhile prostate cancer cells also secrete 
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proteases such as urpkinase and prostate-specific antigen to harness these 
sequestered growth factors.   
Organ specific metastasis depends not only on the anatomy of circulatory 
system but also on the molecular signatures of the cancer cells. The expression 
of certain genes primes cancer cells to metastasize to distinct organs. Membrane 
receptors such as chemokines and integrins play critical roles as they allow 
cancer cells to interact with the surrounding microenvironment. Autocrine 
signaling molecules such as interleukins and growth factors also play significant 
roles in organ specificity because particular ligands expressed by cancer cells 
permit them influence particular cell types in specific tissues. Therefore, 
aberrantly regulated molecules by cancer cells play a dominant role in organ 
specific metastasis.   
 
 
METASTASIS SUPPRESSORS and BREAST CANCER 
Worldwide, breast cancer is not only the most common - with 23% of total 
cancer cases - but also the deadliest cancer type among women with 
approximately half a million deaths annually, corresponding 14% of cancer 
related deaths (65).  In the USA, it is estimated there will be ~234,000 new breast 
24 
 
cancer cases and 40,000 deaths in 2013 (66, 67). Almost all deaths are due to 
metastatic disease. 
As explained in previous sections, the “metastatic cascade” involves a 
series of dramatic cellular events (2, 4, 7, 9, 62). The first step, intravasation, 
involves cancer cell disassociation from the tumor and entry to the blood stream 
(68). Many of these cells die as a result of anoikis, a type of apoptosis due to loss 
of anchorage to the extracellular matrix (69). However, a fraction of these cancer 
cells trapped in the capillaries of distant tissues such as lung, bone, brain and 
liver can resist anoikis (69, 70). These “trapped” cells may survive for extended 
periods of time in a dormant state and some can exit from the blood stream in an 
event called extravasation (71). The final step in metastasis, colonization, is likely 
the rate-limiting step because a cancer cell in a distant tissue is in a very different 
environment than its primary tumor (71). Here, it has to adapt to a new 
environment in order to benefit from different survival signals and cope with 
apoptotic ones.  
Metastasis suppressors are the genes which do not affect the ability of 
transformed cells to form a tumor at primary site but inhibit metastasis (45, 46). 
Currently, there are 23 known metastasis suppressors (Table 1) (42, 43, 46-51, 
72-89). Although, the number of known metastasis suppressor genes has 
recently increased, the field is still at its infancy. The number of metastasis 
suppressors specifically shown to have roles in breast cancer is still limited to five 
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(NME1, BRMS1, DLC1, DRG1 and KAI1). Furthermore, for many metastasis 
suppressors, their mode of regulation is not clear. Previous studies showed that 
the metastasis suppressors CDH1 and CASP-8 are silenced due to promoter 
DNA hypermethylation (44, 90). Moreover, expression levels of metastasis 
suppressors DRG1 and NME1 increase dramatically upon 5-azacytidine (a 
chemical analog of cytidine) treatment (91, 92). These findings suggest that DNA 
methylation is an important mechanism for regulation of metastasis suppressor 
genes.  
Gene 
Symbol 
Gene Name Cancer 
Type 
Method Mechanism Ref. 
BRMS1 Breast cancer 
metastasis 
suppressor 1 
Breast  MMCT chromatin 
remodeling 
(73) 
CDH1 E-cadherin Colon  IHC Cell–cell or 
cell–matrix 
adhesion 
(74) 
CDH2 N-cadherin Osteosarc
oma 
overexpression Cell–cell or 
cell–matrix 
adhesion 
(75) 
CDH11 Cadherin 11 Osteosarc
oma 
overexpression Cell–cell or 
cell–matrix 
adhesion 
(75) 
CASP8 Caspase 8  Neuroblas
toma 
in vivo model, 
overexpression 
apoptosis (43) 
CD44 Indian blood 
group 
Prostate 
adenocarc
inoma 
IHC, q-RT-PCR Cell–cell or 
cell–matrix 
adhesion 
(76) 
DCC Deleted in 
colorectal 
Kidney  overexpression MAPK (77) 
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carcinoma signaling 
DLC1 Deleted in 
Liver Cancer 1 
Breast  microarray, 
overexpression 
Signaling via 
Rho-GTPase 
(78) 
DRG1 Developmenta
lly-regulated 
GTP-binding 
protein 1 
Colon  overexpression N/A (79) 
GSN Gelsolin  Melanoma overexpression Actin 
regulatory 
molecule 
(80) 
KAI1 Cluster of 
Differentiation 
82 
Prostate  LOH, MMCT EGFR 
desensitizatio
n 
(50) 
KISS1 Kisspeptin  Melanoma MMCT G-protein 
coupled 
receptor 
(49) 
MKK4 mitogen-
activated 
protein kinase 
kinase 4  
Prostate  overexpression MAPK 
signaling 
(51) 
MKK6 Mitogen-
activated 
protein kinase 
kinase 6 
Ovarian  overexpression MAPK 
signaling 
(81) 
MKK7 Mitogen-
activated 
protein kinase  
kinase 7  
Prostate  overexpression MAPK 
signaling 
(82) 
NME1 Nucleoside 
diphosphate 
kinase A 
Melanoma differential 
hybridization 
Inhibition of 
ras signaling 
(47) 
NME2 Nucleoside 
diphosphate 
kinase B 
Melanoma overexpression c-myc 
regulation 
(48, 
83) 
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OGR1 Ovarian 
cancer G-
protein 
coupled 
receptor 
Prostate  overexpression G-protein 
coupled 
receptor 
signaling 
(84) 
ARHGD
IB 
Rho GDP-
dissociation 
inhibitor 2 
Bladder  microarray, 
overexpression 
Cytoskeletal 
architecture 
(85) 
PEBP1 Phosphatidylet
hanolamine 
binding protein 
1 
Prostate  IHC, 
overexpression 
Raf-MEK 
signaling 
(86) 
RRM1 Ribonucleotid
e reductase 
M1 
Lung  overexpression PI3K 
signaling 
(87) 
AKAP1
2 
A kinase 
(PRKA) 
anchor protein 
12 
Prostate  overexpression Src signaling (88) 
TIMP TIMP 
metallopeptida
se inhibitor 
Melanoma overexpression Inhibition of 
metalloprotei
nases 
(89) 
IHC: Immunohistochemistry, LOH: Loss of heterozygosity, MMCT: Microcell-
mediated chromosome transfer 
Table 1: List of metastasis suppressor genes. Metastasis suppressor genes, 
the related cancer types, methods used in their identification and affected 
pathways are listed. 
This chapter addressed the complexity of metastasis. I have described the 
multistep nature of metastasis progression and organ specificity of cancer types 
and subtypes by focusing on the molecular actors that dictate the course of the 
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disease. The emphasis for the last section, on metastasis suppressor genes, was 
from the perspective of breast cancer. Although, there have been discoveries of 
metastasis suppressors that function in breast cancer, their number is still limited.  
Identification of novel metastasis suppressors in breast cancer will help us to 
have a better picture of the disease progression and may provide alternatives to 
design successful anti-metastatic therapies. The next chapter will describe how 
we identified serum deprivation response (SDPR) as a candidate metastasis 
suppressor in breast cancer. 
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CHAPTER 2: IDENTIFICATION OF SDPR AS A CANDIDATE METASTASIS 
SUPPRESSOR GENE IN BREAST CANCER 
 
BACKGROUND 
The metastatic progression of breast cancer accounts for the majority of 
disease-related mortality. However, in spite of vast sequencing efforts, mutations 
in potential metastatic suppressor genes, which act as the gatekeepers of 
metastasis, have not been identified (93-95).  Although, a number of metastasis 
suppressors have been identified in recent years (96, 97), the list remains 
incomplete.  
To identify the elusive metastasis suppressor genes which are functionally 
compromised in late-stage disease (1, 2, 45, 98), we took advantage of a well-
established breast cancer progression cell line model system derived from the 
same genetic linage (Fig. 4 and Table 2) (99-101). This model consists of four 
cell lines representing different stages of breast cancer progression. The parental 
MCF10A (MI) cells are spontaneously immortalized (through p16 silencing) 
normal epithelial cells isolated from human breast tissue. MCF10AT1Kcl2 (MII) 
cells were derived from MI cells which were transformed by T24 Ha-ras and then 
xenograft passaged. MCF10CA1h (MIII) and MCF10A1a (MIV) cells were 
isolated from MII xenografts that developed into invasive carcinomas (99, 100). 
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Figure 4: Generation of breast cancer model cell line system. Development 
of model cell line system involved RAS oncogene overexpression and series of 
xenografts performed on immunodeficient mice.  
 MI MII MIII MIV 
Represented 
stage in the 
model 
Normal 
epithelium 
Carcinoma 
in-situ 
Carcinoma Metastatic 
carcinoma 
Description Spontaneously 
immortalized 
Transfected 
HRAS 
oncogene  
Derived from 
xenograph 
implant MII 
Derived from 
xenograph 
implant MII 
Tumorigenicity 
in nude mice 
Non-
tumorigenic 
Benign 
hyperplastic 
lesions, 25%  
of the time 
forms 
carcinoma 
Well-
differentiated 
carcinomas 
Poorly 
differentiated 
carcinomas, 
lung 
metastasis 
upon tail vein 
injection 
Table 2: Breast cancer model cell line system. Table summarizes the features 
of each cell line used in the breast cancer progression model.  
MII cells produce benign lesions that have the potential to develop into 
invasive carcinoma (25% of the time) when injected into immunodeficient mice 
and hence they represent carcinoma in-situ in our model. MIII cells generate well 
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differentiated invasive carcinoma 100% of the time when injected into 
immunodeficient mice. Therefore, MIII cells represent invasive carcinoma, 
without metastatic potential. However, MIV cells not only generate poorly 
differentiated invasive carcinoma 100% of the time upon injection into 
immunodeficient mice but also form lung metastasis upon tail vein injections. As 
the most aggressive cell line, MIV represents an invasive carcinoma that has 
metastatic potential.  
Since these cell lines share the same genetic background and differ in 
their metastatic potential, we hypothesized they represented a suitable model in 
which to identify novel metastasis suppressor genes. Indeed, the gene 
expression profiling of the model cell lines and by leveraging large amounts of 
publically available data (102-105) and applying multiple bioinformatics filters we 
identified a promising candidate metastasis suppressor gene, SDPR (also known 
as cavin-2). In this chapter, I will present the data that lead us to hypothesize that 
SDPR functions as a metastasis suppressor in breast cancer. 
MATERIALS and METHODS 
Cell culture 
 MCF-10A based cell lines, MI, MII, MIII and MIV were cultured in 
DMEM/F12 1:1 mixture medium (Life Technologies, Carlsbad, CA) supplemented 
with 5% horse serum (Life Technologies, Carlsbad, CA), 1% 
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penicillin/streptomycin solution (Life Technologies, Carlsbad, CA), 10 µg/ml 
insulin (Sigma-Aldrich, St. Louis, MO), 0.1 µg/ml cholera toxin (Sigma-Aldrich, St. 
Louis, MO), 20 ng/ml epidermal growth factor (R&D Systems, Minneapolis, MN) 
and 0.5 µg/ml hydroxycortisone (Sigma-Aldrich, St. Louis, MO). Cell lines were 
maintained at 37°C in a humidified incubator with 5% CO2. 
Gene expression profiling 
 Total RNA was isolated from MII, MIII and MIV cells lines in triplicate 
using Trizol, and RNA samples were cleaned with Qiagen RNeasy Kit following 
manufacturer’s protocol. Following RNA quality control, samples were hybridized 
to GeneChip Human Genome U133 Plus 2.0 Arrays from Affymetrix (Whole data 
and detailed methods will be available in public Gene Expression Omnibus 
(GEO) database and the accession number will be available in our related peer 
reviewed publication). Hierarchical clustering has been performed on genes 
whose expression was statistically at least two fold different among cell lines. 
Soft agar colony formation assay 
 2X DMEM/F12 1:1 mixture medium was prepared with 10% horse serum, 
2% penicillin/streptomycin solution, 20 µg/ml insulin, 0.2 µg/ml cholera toxin, 40 
ng/ml epidermal growth factor and 1 µg/ml hydroxycortisone. Low melting point, 
DNA grade agarose was used to prepare 0.8% agarose. 0.8 agarose and 2X 
DMEM/F12 medium mixed to have 0.4% agarose in DMEM/F12 medium. 6 cm 
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tissue culture plates were coated with 0.4% agarose in DMEM/F12. Then, cells 
were seeded in 0.25% agarose in DMEM/F12 on top of polymerized first layer. 
Plates were incubated three weeks at 37°C in a humidified incubator with 5% 
CO2. To visualize, formed colonies were stained with 0.5% crystal violet solution 
and pictures were captured with Nikon D80 digital SLR camera.  
Quantitative reverse transcriptase PCR (Q-RT-PCR) 
 Total RNA was isolated with Trizol (Life Technologies) and cDNA 
synthesis was carried out by using random primers and SuperScript II Reverse 
Transcriptase (Life Technologies). Quantitative RT-PCR was performed with 
SYBR Green PCR Master Mix (Life Technologies) and Applied Biosystems 
7900HT Sequence Detection System was used to run the PCR reactions.  
Relative mRNA expression of gene of interest was calculated by the ΔΔCt 
method and normalization was done according to actin mRNA levels.  The 
primers used are listed (Table 3).  
Genes from cluster 7 
Gene 
name 
Forward Reverse 
SLPI AGGCTCTGGAAAGTCCTTCA TCTGGCACTCAGGTTTCTTG 
LPL CAGCCAGGATGTAACATTGG CTCGTGGGAGCACTTCACTA 
PLLP CAAGCAACACGTAGCACCTT GAGAGGTTGGTTGAAACGGT 
KRT6A GGGTGTGATCTCACTGTTGG AGTCCTGGAAGGTGAGCTTG 
KLF4 GGCACTACCGTAAACACACG CTGGCAGTGTGGGTCATATC 
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MIA ATTGTCCGAGAGGACCAGAC CACTGGCAGTAGAAATCCCA 
CYP1A1 AAACCCAGCTGACTTCATCC TGCTCCTTGACCATCTTCTG 
ACAT2 GCCTTGCAGTCCAGTCAATA TAAGCCAAGTGAGGAGCCTT 
PDZD2 CCACAGGAAACCCTTGATCT TGTGGTGTTTCTGTCAGGGT 
KRT14 ATTGAGAGCCTGAAGGAGGA ATTGACATCTCCACCCACCT 
SCNN1B CCAGAGCTTGTGTCCTTCAA GGGTAGGAACCAGGTGAAGA 
AQP3 CAGTGGGACGTGTTTCTGTC CCCGGATCCCTAAGACTGTA 
DEFB1 TCATTACAATTGCGTCAGCA TTCTGCGTCATTTCTTCTGG 
PLAC8 GCAACTCTTTGCTGTCCTCA AAAGTACGCATGGCTCTCCT 
ZNF365 ATTCCGACAGGGTGTCTTTC AAAGAAGACGGCAGAGGTGT 
S100A4 TTCTTGGTTTGGTGCTTCTG AGCAGTCAGGATCAACACGT
A 
ZNF44 GGCCCTGTGTTATGGAACTT GATATCCACTAGGCCCTCCA 
GJA5 ACTGACAGGCTCAAGAGCAA TTCTTCACACTCTGGCTGCT 
PCSK5 GGTGACTGGGTCCTTGAAGT GTTGGTGAATATGGCTGCAC 
CDA GCAGGCAAGTCATGAGAGAG CATTCTCTGGCTGTCACTGG 
GABRA2 TTCGCCTCCTTCTACACCTC ACTGCAGCAGCCAAGAGAG 
CORO2A TTGAAATTTGAGAAGGGCAA TCCAGGAGCTCCACCTAAAT 
DHRS9 TTGCTCCATCTACCAGAACAA AAAGCGGACAGACAAACAGA 
LYPD3 CAACCAGTCAGACTCCGAGA GGATACTGCCCTGAATTGCT 
ARL4D AGAAGAGACGGTGACCCAAG TCCTTCATTGAGGTGGACAG 
 
Genes from cluster 6 
Gene 
name 
Forward Reverse 
SSBP3 TCCCACCCCTTGCCCTTTCC GGTGGAAGGGCTTGGGCACA 
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MYADM GTGCACTTTCGCTGGGTTCCG
T 
GGGGGAGGTAGGCCGTTAG
C 
ZNF302 GACGGTGAGGCCCTGCTGAG TGGTTGAAGGCTGCCCCACT 
SLC14A1 CCTTGTCGTGGAGGTGGGCAA
AT 
GCCGCCAATCAAAGACCGTC
C 
MYLIP CCGGACAAGGGTCCGCAGAG GCGTCCGGCCTCGTCACATA 
DHRS9 TCATACCAGAAGGAGCACCCA
CCT 
AGACCCAACAAGAGGTCCTG
CG 
SCNN1G GGCCCAGAGCCCTTGGAGTG CCCAGAGCATGGCCCACCAT 
FKBP1B GGCCAAACGTGTGTGGTGCA CCCCAAGCTCATCTGGGCTG 
HIST1H2
BD 
TTGCCAAGGGAGAGACATGAA
GACA 
ACCAGTGTGCAGCAAACCAG
GAT 
SEPP1 TCAGAGTGTGCTGCTGTGGCT
T 
CTCCACATTGCTGGGGTTGT
CACA 
AOX1 GGTGCCCGCTACTTCCCAGAA
C 
CACCTTGCGGCCGTTCACGT 
SORBS2 TGATCACAGCCACGCAGGCC CAGTCCAGTGCCCGTCCCAG 
SDPR AGTCACGGTGCTCACGCTCC GTTGCTGGTGGAGGCCTGGT 
BIN1 TTTCGCGGCTGCGCAGAAAG AGGCCTCTGCTGGCTGAGAT
G 
EFEMP1 AAGGCGTGGAAATGCCACTTT
GAG 
CCTGTGACTTGACCAGCGCC
A 
MT1E TTCCAACTGCCTGACTGCTTG
TTCG 
CTCTTTGCACTTGCAGGAGC
CG 
SGK1 ACGTCTTTCTGTCTCCCCGCG
G 
ACCATGCCCCTCATCCTGGA
GT 
CDH19 GCGGGAACGCAAGACTCGGA GGCACTGTCGGGGCCAACTT 
LIMCH1 CATCCCGGCGCTTGAGAGGA TTCTGCGCCTCGGAGAAGGC 
TACC1 CTTCCCGGCTAGTGGAGCCC CCCCAGGTCCTGCCAATCCG 
36 
 
KLF9 ACGCCCTTGTGATTGGCCGA ACGTTCCAGCTTGCGGAGCT 
BCL11B CCCACCCTCACTCATCCGTGA
TCA 
AGGGCTGCTTGCATGTTGTG
C 
LPCAT2 TCGCTTCGGCCGGGTTCTAC ACAATCTGGACCCGCCTCGC 
TFPI CAAGGCGGATGATGGCCCAT
GT 
ACGACACAATCCTCTGTCTGC
TGG 
HOPX TCCCCGTCTTCTCTCAGCCAC
A 
GCAGCGTGGGCAGGAGGTAA 
GNG2 CTGTCGTGGAGGTGACCGTG
G 
GCTCCTGGGCTGCTGACAGT 
TIMP3 GCTCTCAGCTCTCGGGCCAG TGTCTCCTGGGGGCCACAGT 
RHOBTB
3 
GCTCCTTTGTGTCCAGCCGC CAGCTGACCGCAGTCCCCTC 
ACTB CGAGCACAGAGCCTCGCCTTT
GCC 
TGTCGACGACGAGCGCGGC
GATAT 
Table 3: Primer sets used in Q-RT-PCR. 
The PCR reaction conditions were 50°C, 2 min; 95°C, 12 min; 40 cycles x 
[95°C 20 sec, 59°C 1 min, 72°C 15 sec]; 72°C 10 min. 
Meta-analysis 
Oncomine™(102) and Kaplan Meier Plotter (103) were used in our in-
silico analyses.  
Statistical analysis 
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p-values were calculated by one tailed, paired t-test. p-values smaller than 
0.05 were considered significant. In all experiments error bars represent standard 
error.   
RESULTS 
Candidate metastasis suppressor genes that are repressed in the 
metastatic breast cancer cell line, MIV 
We decided to perform gene profiling analyses on model cell lines to 
identify candidate metastasis suppressor genes in breast cancer. We excluded 
MI cell line in our analysis because many of the differences between MI and 
other cell lines can be attributed to RAS oncogene transformation. Therefore, we 
limited out microarray study to MII, MIII and MIV. To further characterize these 
three cell lines prior to the gene profiling experiment, we performed colony 
formation assay (Fig. 5). MII cells cannot form any observable colonies whereas 
MIII and MIV can. Metastatic MIV cells can form significantly more colonies 
compared to non- metastatic MIII cells. This result was in line with their in-vivo 
characteristics and recapitulated their tumorigenesis potential. 
Next, we performed gene profiling analysis. From the microarray data, 
genes whose expression levels were at least two fold different according to 
student’s t-test among the cell lines were further analyzed to draw hierarchical 
clustering graph based on their z-scores (Fig. 6). Genes in the magnified clusters 
38 
 
Figure 5: Characterization of breast cancer model cell lines. Top panel   
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shows the colony formation potential of model cell lines. Graph depicts the 
quantification of soft agar assay (n=) and lower panel shows the morphology of 
each cell line. 
(Cluster 6 and 7) are dramatically repressed in MIV cells. While in cluster 6, 
genes are expressed equally high in MII and MIII and are repressed in metastatic 
MIV, in cluster 7, expression levels are high in MII, moderate in MIII and low in 
MIV. Overall, the expression pattern of these genes is inversely correlated with 
the metastatic potential of the cell lines. Therefore, we hypothesized that these 
two clusters harbor metastasis suppressors. 
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Figure 6: Hierarchical clustering map of differentially expressed genes 
among model cell lines. Genes whose expressions differed by a minimum of 2-
fold were used to plot hierarchical clustering map that highlighted patterns of 
gene expression in 12 distinct clusters. Among these clusters, cluster 6 and 7 
drew our attention since the genes were significantly down-regulated  in 
metastatic MIV cell line compared to their non-metastatic counterparts, indicating 
an inverse relation between gene expression and metastatic potential. 
Since the two clusters of interest contained a total of 153 genes, we 
employed a strategy to select the most promising metastasis suppressors (Fig. 
7). We performed meta-analysis on Oncomine™ and Kaplan Meier Plotter in 
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conjunction with Q-RT-PCR. Each step let us focus on a smaller number of 
candidate metastasis suppressors. 
  
Figure 7: Approach to narrow down number of candidate metastasis 
suppressor genes.  
Oncomine™ analysis on candidate metastasis suppressor genes 
We interrogated each gene in the two clusters of interest by using the 
Oncomine™ database which revealed that 51 out of 153 genes were down-
regulated  in cancers compared to their respective control tissues (Table 3).  The 
analysis on Oncomine™ implied that the genes identified from hierarchical 
clustering across the model cell lines were not model specific since independent 
gene expression studies from clinical samples revealed similar results. 
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Q-RT-PCR analysis revealed eleven candidate metastasis suppressor 
genes 
We tested the reproducibility of our microarray data by Q-RT-PCR for the 
genes that passed the Oncomine™ filter.  We confirmed the expression levels of 
23 genes, out of the total 51, were consistent in both the microarray and PCR 
analysis (Fig. 8). Twelve out of 23 genes were subsequently excluded because 
of the low significance (we required minimum 2-fold difference in expression 
levels of the genes between cell lines) among cell lines. At the end, we narrowed 
down the number of candidate metastasis suppressor genes to 11 (Fig. 9). 
Interestingly, 8 out of 11 candidate metastasis suppressor genes we proposed to 
study do not have any reported function in breast cancer (Table 4). On the other 
hand, LPL has been reported as a candidate metastasis suppressor that is 
frequently lost in metastases but there are no reports confirming this function 
(106). While PDZD2 has been shown to induce quiescence of MCF-7 cell line 
(107), more studies are necessary to ascertain its function in breast cancer 
metastasis. Surprisingly, our preliminary data suggested a known pro-metastatic 
factor, S100A4 as a metastasis suppressor (108). It is noteworthy that S100A4 
has been shown to be significantly down-regulated  in tumors compared to 
matched controls in six different studies on Oncomine™. Moreover, it is highly 
suppressed in metastatic cell line MIV compared to non-metastatic cell line MII 
and S100A4 knockout mice develop spontaneous lung tumors due to 
43 
 
destabilization of p53 (109). Therefore, S100A4 remains as an attractive 
candidate to study. 
High SDPR expression is associated with longer relapse-free survival in 
breast cancer  
We used Kaplan-Meier Plotter, an online software, to interrogate the 
possible biological significance of our candidate genes as the final step in our 
strategy to pinpoint possible driver genes responsible for metastatic potential of 
MIV cell line (103). By using this software, one can extract the relapse free 
survival data of breast cancer patients based on the expression levels of a gene 
of interest. The cohort used in this online tool consists of 2270 patients and one 
can split this cohort into two according to the median expression level of the gene 
of interest. The relapse free survival curves based on expression levels of our 
candidate metastasis suppressor genes were plotted (Fig. 10). We could not 
generate the relapse-free survival curve for MYADM since it was not represented 
in the microarray chip used in this study. 
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Figure 8: Relative expression levels of candidate metastasis suppressor 
genes that followed the pattern observed in microarray assay. Number of 
candidate genes decreased from 51 following Oncomine™ analysis to 23, n=3. 
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Figure 9: Relative expression levels of final 11 candidate metastasis 
suppressor genes.  
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Gene 
symbol 
Gene name Known 
function 
Transgenic mouse & 
corresponding 
phenotype 
Relation to 
breast 
cancer 
LPL Lipoprotein 
lipase 
Hydrolyzes l
ipids in lipo
proteins 
-Lethal within 18hrs of 
birth (110) 
-Lethal within 48hrs of 
birth Severely elevated 
triglyceride levels; 
chylomicrons 
cyanosis (111) 
Down-
regulated  
ACAT2 Acetyl-
Coenzyme A 
acetyltransfe
rase 2 
Lipid 
metabolism 
-“Viable and healthy”, 
decreased cholesterol 
absorption and 
cholesterol ester 
synthesis (112) 
N/A 
PDZD2 PDZ domain 
containing 2 
Intracellular 
signaling 
N/A Induces 
quiescence 
of MCF-7 
cells 
DEFB1 Beta-
defensin 1 
Antimicrobi
al peptide 
-“No visible 
abnormalities, fertile.”; 
increased presence of 
bacteria in urine (113) 
-“ fewer offspring but 
normal and 
healthy”;  clearance of 
influenzae bacteria 
significantly less 
efficient (114) 
N/A 
S100A4 Protein 
S100-A4 
Cell 
signaling -“viable, no 
abnormalities but fewer 
female offspring”; 
spontaneous tumor 
development in lungs 
(109) 
Pro-
metastatic 
ZNF44 Zinc finger N/A N/A N/A 
47 
 
protein 44 
MYAD
M 
Myeloid-
associated 
differentiatio
n marker 
N/A N/A N/A 
MYLIP Myosin 
regulatory 
light chain 
interacting 
protein 
-IDOL 
"Inducible 
Degrader of 
the LDL 
receptor" 
LDL 
receptor 
degredation 
N/A N/A 
SDPR Serum 
deprivation 
response 
Endocytosis 
-caveolae 
Formation 
Significantly less 
number of caveolae 
formation in lung 
endothelial cells (115) 
N/A 
AOX1 Aldehyde 
oxidase 1 
Metabolic 
enzyme 
N/A N/A 
MT1E Metallothion
ein-1E 
N/A N/A N/A 
Table 4: Candidate metastasis suppressor genes. 8 of 11 candidate genes 
had no reports relating them to breast cancer progression.  
High expression level of candidate genes, SDPR, DEFB1, ZNF44, AOX1 
and MYLIP were positively correlated with relapse-free survival and the 
differences in each case were statistically significant. The lowest p-value among 
these five genes belonged to SDPR and hence it was selected as the primary 
gene of interest for our studies. 
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Figure 10: Relapse free survival curves based on expression of candidate 
metastasis suppressor genes. Curves were generated by Kaplan-Meier Plotter 
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based on expression levels of candidate genes. Red line indicates the patient 
group with higher levels of the candidate gene whereas black line indicates the 
patient group with lower levels. *: Statistically significant, p value < 0.05, **: Gene 
with the lowest p value. 
 
DISCUSSION 
In this chapter, we examined gene expression profiles of MII, MIII and MIV 
cells to identify genes down-regulated  in the MIV line, relative to MII and MIII, 
which might function as metastasis suppressors. Hierarchical clustering across 
these three cell lines revealed two clusters with genes specifically repressed in 
MIV cells. While in cluster 6, genes are expressed equally high in MII and MIII 
and are repressed in metastatic MIV, in cluster 7, expression levels are high in 
MII, moderate in MIII and low in MIV. Overall, the expression pattern of these 
genes is inversely correlated with the metastatic potential of the cell lines. 
Therefore, we hypothesized that these clusters harbor metastasis suppressors.  
Since the two clusters of interest contained a total of 153 genes, we 
employed the following strategy to select the most promising metastasis 
suppressors. First, we interrogated each gene using Oncomine™ database 
which revealed that 51 out of 153 genes were down-regulated  in cancers 
compared to control tissues (102).  This analysis on Oncomine™ suggested that 
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results we obtained from hierarchical clustering across the model cell lines were 
probably not model specific since independent gene expression studies from 
clinical samples revealed similar results. Next, we confirmed the reproducibility of 
our microarray results by quantitative RT-PCR and observed the expected 
expression pattern for 11 out of 51 genes. Finally, we used in silico Kaplan-Meier 
analysis to generate relapse-free survival curves based on expression level of 
each gene (103), which resulted in the emergence of SDPR as the most 
significant candidate. Based on these data we hypothesized that SDPR acts 
as a metastasis suppressor in breast cancer. 
In the next chapter, we provide evidence on the function of SDPR as a 
metastasis suppressor in breast cancer, present data regarding its expression in 
clinical samples and also try to explain how it is repressed in metastatic breast 
cancer cells. 
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CHAPTER 3: FUNCTION OF SDPR AS A METASTASIS SUPPRESSOR IN 
BREAST CANCER 
BACKGROUND 
The data we generated based on gene profiling of breast cancer 
progression model let us hypothesize that SDPR functions as a metastasis 
suppressor in breast cancer. To test this hypothesis we have performed in vivo 
tumorigenesis and metastasis assays and to elucidate its mechanism of action 
we undertook in vitro cellular and molecular assays. Before going into the details 
of these experiments, I will cover the known function of SDPR in this section. 
Studies on SDPR function have been mostly focused on its role as a 
regulator of caveolae formation (115-118), and its functional involvement in 
cancer has not been reported. However, it is noteworthy that SDPR expression is 
down-regulated significantly in not only breast cancer but also cancers of kidney 
and prostate (119-121). Moreover, SDPR protein downregulation is observed in 
serum from patients with malignant kidney tumors and hence suggested as a 
possible diagnostic tool to discriminate malignant tumors from benign formations 
(122). SDPR is localized to 2q32-33, a region with a significant level of loss of 
heterozygosity (LOH) and a high degree of recurrence in breast cancer (123, 
124). Interestingly, CASP8, which is subject to truncating mutations in breast 
cancer as determined by exome sequence analysis, and implicated as a 
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metastasis suppressor, also localizes to 2q33 which may hint at the possible 
involvement of SDPR in breast cancer (43, 95).  
As its name implies, SDPR mRNA levels increases following serum 
starvation in NIH3T3 cells (125). Serum starvation caused growth arrest of 
NIH3T3 cells with concomitant SDPR mRNA induction but it was not clear 
whether SDPR was a driver of the arrest or a consequence thereof. Additionally, 
treatment of prostate cancer PC-3 cells with insulin-like growth factor 1 (IGF-1), 
transforming growth factor beta 1 (TGFβ1) or interleukin 6 (IL-6) caused increase 
SDPR expression (126). This may indicate that repression of SDPR may be a 
common reaction to low nutritional conditions that cancer cells are likely to 
encounter as the tumor progress to the metastatic stage. The SDPR mRNA 
expression is especially high in adult heart and lung tissue but it is detectable in 
other major tissues such as liver, skeletal muscle, kidney and pancreas (123).  
As a regulator of caveolae, SDPR interacts with other regulatory subunits 
of cavin complex, including cavin 1 (PTRF) and 3 (SRBC) to control the formation 
of caveolin protein oligomerization (117, 118) (Fig. 11). Overexpression of SDPR 
caused significantly larger caveolae and knockdown of SDPR resulted in fewer 
number of caveolae for a given membrane area in HeLa cells (116). SDPR-/- 
mouse did not show a gross phenotype but its lung endothelial cells showed 
drastically reduced number of caveolae (115). These observations indicate a 
critical role played by SDPR in caveolae regulation. 
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Figure 11: Caveolae. Formation of caveolae depends on interactions between 
structural caveolin proteins (CAV1, CAV2 and CAV3) and regulatory cavins 
(Cavin 1, 3 and SDPR).  
In the following sections, we demonstrate the metastasis suppressor 
function of SDPR and provide a possible mechanism for this role as well as 
insights into its repression during cancer progression  
.  
54 
 
MATERIALS and METHODS 
Cell culture 
MCF-10A based cell lines, which include NeoT, MII, MIII, MIV, MIVpQ, 
MIVpQ.SDPR, NeoTshGFP and NeoTshSDPR, were cultured in DMEM/F12 1:1 
mixture medium (Life Technologies, Carlsbad, CA) supplemented with 5% horse 
serum (Life Technologies, Carlsbad, CA), 1% penicillin / streptomycin solution 
(Life Technologies, Carlsbad, CA), 10 µg/ml insulin (Sigma-Aldrich, St. Louis, 
MO), 0.1 µg/ml cholera toxin (Sigma-Aldrich, St. Louis, MO), 20 ng/ml epidermal 
growth factor (R&D Systems, Minneapolis, MN) and 0.5 µg/ml hydroxycortisone 
(Sigma-Aldrich, St. Louis, MO). MDA-MB-231 based cell lines, MDA-MB-
231LM2, MDA-MB-231LM2pQ, MDA-MB-231LM2pQ.SDPR and MDA-MB-468, 
UACC812, Hs578T were cultured in DMEM medium (Life Technologies, 
Carlsbad, CA) supplemented with 10% FBS (Atlanta Biologicals, Flowery Branch, 
GA ) and 1% penicillin / streptomycin solution. T47D and BT549 cell lines were 
cultured in RPMI (Life Technologies, Carlsbad, CA) containing 10% FBS and 1% 
penicillin / streptomycin solution. SUM159 cell line was cultured in Ham’s F/12 
supplemented with 5% FBS, 1% penicillin / streptomycin solution, 5 μg/ml insulin 
and 1 μg/ml hydrocortisone. Cell lines were maintained at 37°C in a humidified 
incubator with 5% CO2. 
In vivo metastasis and tumorigenesis assays 
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Six-week-old female NOD.CB17-Prkdcscid/J mice (The Jackson 
Laboratory, Bar Harbor, ME) were used for all in vivo metastasis and 
tumorigenesis assays. For in vivo metastasis assays involving MIV based cell 
lines, 5x105 cells were injected through the tail vein, and mice were monitored by 
bioluminescent imaging for 11 weeks. For in vivo metastasis assays involving 
LM2 based cell lines, 1x106 cells were injected through the tail vein, and mice 
were monitored for 7 weeks. Bioluminescence imaging was performed with the 
Caliper IVIS Spectrum Imaging System (PerkinElmer, Waltham, MA). Prior to 
imaging, mice were injected with D-luciferin (150mg/kg - intraperitoneal). On 
necroscopy, lungs were extracted and imaged in order to count the number of 
macrometastases in each lung.  
In vivo tumorigenesis assays were done by subcutaneously injecting 
5x105 MIV cells. Mice were monitored for 5 weeks by bioluminescent imaging 
and tumor sizes were assessed at the end of the experiment by measurement of 
tumor weight.   
Antibodies 
Anti-SDPR antibodies were obtained from Sigma (St. Louis, MO). 
Antibodies against total p53, phosphorylated p53 (Ser15), PUMA, Bax, Bad, Bid, 
Bim, Bcl-xL, total Erk, phosphorylated Erk (Thr202/Tyr204), total p65, 
phosphorylated p65 (Ser536) and Casp3 were obtained from Cell Signaling 
(Danvers, MA). Anti-Mdm2 antibody was from Calbiochem (EMD Millipore, 
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Billerica, MA). Anti-beta Actin antibody was obtained from Abcam (Cambridge, 
UK). Anti-HIS-tag antibody was obtained from Roche (Basel, Switzerland).  
Western blot analysis 
To detect proteins of interest, cell lysates were mixed with 4x Laemmli’s 
reducing buffer (Boston Bioproducts, Ashland, MA), boiled for 5 minutes and run 
on SDS-PAGE gels cast at 8 to 20% depending on protein of interest. Following 
the gel run, proteins were immobilized on PVDF membranes for primary antibody 
incubations, which were done overnight in a cold room.  Secondary antibodies 
conjugated to peroxidase were detected by chemiluminescence with ECL 
solution (Perkin-Elmer, Waltham, MA).  Actin signal was used to ensure equal 
protein loading.        
Annexin V staining 
To quantify the apoptotic population, we used the Anexin-V Apoptosis 
Detection Kit FITC from eBioscience (San Diego, CA) and followed the provided 
protocol. We analyzed the samples using a FACSCalibur™ run by Cellquest Pro 
v5.2 software at Boston University School of Medicine Flow Cytometry Core 
Facility. Flow cytometry data was analyzed with FlowJo (Tree Star). 
Cell migration assays 
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For the scratch wound healing assay, cells were grown to confluence and 
a scratch wound created with a 200 µl pipette tip. The rate of wound closure was 
monitored by light microscopy at 0 and 20 hours.  
The Boyden chamber migration assay was performed using 6-well 
Transwell plates with an 8 µm pore (Corning, Tewksbury, MA). Following 
trypsinization and counting, one hundred thousand cells were seeded on the 
upper compartment of the chamber in serum-free DMEM/F12 medium and 
allowed to migrate towards either serum-free or complete medium for 20 hours. 
The top side of the membrane was then cleaned with cotton swabs and the 
migrated cells stained with 0.5% crystal violet solution and visualized by light 
microscopy. 
Cell proliferation assay 
Five thousand cells per well were seeded in 96-well plates and the 
number of cells assessed daily for five days using the MTS tetrazolium/PMS 
assay kit (Promega, Madison, WI) according to the manufacturer’s protocol and 
the absorbance at 490nm recorded by Bio-Tek (Winooski, VT) µQuant plate 
reader.  
3D cell culture 
Ninety-six-well plates were coated with 100µl of Matrigel (BD Biosciences 
San Jose, California) and five thousand cells were seeded to each well in 100 µl 
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of 2% Matrigel/complete medium solution as described previously (127). Cell 
growth was monitored daily for five days by light microscopy. 
Drug treatments 
Cells were grown in complete medium overnight prior to treatment with 5 
μmol/L 5’-aza-deoxycytidine (Sigma-Aldrich, St. Louis, MO) for 72 hours.  
Quantitative reverse transcriptase PCR (Q-RT-PCR) 
 Total RNA was isolated with Trizol (Life Technologies) and cDNA 
synthesis was carried by using random primers and SuperScript II Reverse 
Transcriptase (Life Technologies). Quantitative RT-PCR was performed with 
SYBR Green PCR Master Mix (Life Technologies) and Applied Biosystems 
7900HT Sequence Detection System was used to run the PCR reactions.  
Relative mRNA expression of gene of interest was calculated by the ΔΔCt 
method and normalization was done according to actin mRNA levels.  The 
primers used are: 
Gene Forward Reverse 
SDP
R 
AGTCACGGTGCTCACGCTCC GTTGCTGGTGGAGGCCTGGT 
ACTB CGAGCACAGAGCCTCGCCTTT
GCC 
TGTCGACGACGAGCGCGGCG
ATAT 
The PCR reaction conditions were 50°C, 2 min; 95°C, 12 min; 40 cycles x 
[95°C 20 sec, 59°C 1 min, 72°C 15 sec]; 72°C 10 min. 
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Quantitative methylation specific PCR (Q-MSP) 
Genomic DNA was isolated by Qiagen DNeasy Blood & Tissue Kit 
following manufacturer’s protocol. Bisulfite conversion reactions were carried out 
by EpiTect Bisulfite Kits from Qiagen following the manufacturer’s protocol. 
Methylation specific primer sets were designed using the MethPrimer (128) 
online software. Primer sequences were: 
Methylated-specific forward:  5’-TCGGGATAATTTATAGGTGAACGT -3’ 
Methylated-specific reverse: 5’-AAATCATTCTAAATACCCTTCACGA -3’ 
Unmethylated-specific forward: 5’-TTTGGGATAATTTATAGGTGAATGT-3’  
Unmethylated-specific reverse: 5’-AATCATTCTAAATACCCTTCACAAA-3’ 
The PCR reaction conditions were 50°C, 2 min; 95°C, 12 min; 40 cycles x 
[95°C 20 sec, 59°C 1 min, 72°C 15 sec]; 72°C 10 min. 
Luciferase reporter assays 
Transient transfection of reporter constructs (luciferase gene driven by 
PUMA, Bax or Mdm2 promoters were generous gifts from Drs. Bert Vogelstein 
and Jian Yu, Howard Hughes Medical Institute at Johns Hopkins) were 
performed using FuGENE transfection reagent (Roche, Basel, Switzerland) 
following the manufacturer’s protocol. As a transfection control, renilla luciferase 
was co-transfected with the reporter constructs. After 48 hours of transfection, 
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cells were lysed in Passive Lysis Buffer (Promega, Dual-Luciferase Reporter 
Assay) and luciferase activity was measured at 570 nm. Subsequent to of 
reaction termination, renilla luciferase activity was measured as internal control.  
Luciferase/renilla ratio was used to compare activity of reporter constructs in 
different samples. 
Cloning to overexpress and knockdown SDPR 
We amplified the SDPR coding region by using the following primer pair: 
F: 5’ GAGA GCGGCCGC ATG 
GGAGAGGACGCTGCACAGGCCGAAAAGTTCCAGC 3’ 
R: 5’ GAGA TTAATTAA TCA GTGGTGATGGTGATGATG 
GGAGGTCTGGTGCACC 3’ 
Filler Sequence, Restriction Sites, Start/Stop Codons, 6-His Tag, SDPR specific 
sequence 
Template cDNA was synthesized by using total RNA isolated from MII 
cells. Amplified SDPR PCR products were run on 1% agarose gel to confirm their 
size and quality. Gel extraction was done by Qiagen QIAquick Gel Extraction Kit 
(Limburg, Netherlands). Then, restriction enzyme digestion was performed by 
using NotI enzyme for 2 hours at 37⁰C in suggested reaction conditions by New 
England BioLabs (Ipswich, MA). Reaction was cleaned using Qiagen QIAquick 
PCR Purification Kit. A second restriction enzyme digestion was done by using 
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PacI enzyme in suggested reaction conditions by New England BioLabs for 2 
hours at 37⁰C and the reaction was cleaned by Qiagen QIAquick PCR 
Purification Kit. The pQCXIP retroviral expression vector was prepared for 
ligation by performing restriction enzyme digestions with NotI and PacI enzymes. 
Ligation of SDPR into pQCXIP vector was performed using T4 DNA ligase in 
suggested reaction conditions by New England BioLabs for 20 minutes at room 
temperature. DNA from the ligation reaction was used to transform of JM109 E. 
coli bacteria strain. Five colonies, which were able to grow in ampicillin plates, 
were picked for mini-prep in order to check for the SDPR inserts. A confirmed 
SDPR clone was used in midi-prep and it was checked a second time by 
sequencing. 
To create stable cell lines expressing SDPR, we co-transfection 
pQXVIP.SDPR and pCL-Ampho pLKO packaging plasmid with 2:1 ratio in 293FT 
cells, which were allowed to produce virus for 48 hours. Target cells were 
transfected with the harvested media in the presence of polybrene (Sigma-
Aldrich, St. Louis, MO). Puromycin (2 μg/ml) selection was performed to create 
stable cell lines and SDPR expression is confirmed by western blot analysis. 
We used following four oligos to target SDPR for knockdown: 
#1: 5’-GCAGTGAGCAGATGCCAAATG-3’    
#2: 5’-GGCACAGAAGGTACGCTATGA-3’ 
#3: 5’-GCATCCAGAATGACCTCACCA-3’ 
#4: 5’-CCAGCCTGAAGAAGTGGATAGCCTCAAG-3’ 
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These oligonucleotides were ligated into pLKO-puro.1 lentiviral vectors 
(129). We co-transfected the pLKO.shSDPR plasmid, psPAX2 and pMD2.G, in a 
5:3:1 ratio, in 293FT cells, which were allowed to produce virus for 48 hours.  
Target cells were transfected with the harvested media in the presence of 
polybrene (Sigma-Aldrich, St. Louis, MO). Pooled cells were selected by 
treatment with 2 μg/ml of puromycin. Knockdown was confirmed at protein level. 
Statistical analysis 
For growth curve comparison, Analysis of variance (ANOVA) test was 
used. For the rest of the experiments, p-values were calculated by one tailed, 
paired t-test. p-values smaller than 0.05 were considered significant. In all 
experiments error bars represent standard error.   
Tissue processing and hematoxylin and eosin staining 
Following extraction, lungs were immediately fixed with 4% 
paraformaldehyde with overnight incubation in cold room. Following day, fixed 
lungs were embedded in paraffin and 5 micron sections were cut for hematoxylin 
and eosin staining. Pictures of stained slides were captured by light microscopy 
using Nikon E4300 digital camera. 
RESULTS 
SDPR suppresses metastatic potential of breast cancer cell lines 
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To test if SDPR could function as a metastasis suppressor, we generated 
MIV cells with stable expression of SDPR (Fig. 12). Following tail vein injections 
of MIV cells, we observed that SDPR overexpression caused a 52% reduction in 
the percentage of mice that developed metastases and the number of metastatic 
nodules per mouse was decreased significantly from 2.3 to 0.4 (Fig. 13 and 14). 
The effect of SDPR overexpression on metastasis potential of MIV cells was 
clearly apparent in hematoxylin and eosin staining of the lung sections (Fig. 15). 
These observations suggested that SDPR was able to suppress the metastatic 
potential of MIV cells. However, interestingly, when we tested the possible effect 
of SDPR on tumorigenesis, we did not observe a change (Fig. 16). This data 
suggested that SDPR can indeed suppress metastatic potential of MIV cells. 
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Figure 12: SDPR overexpression in MIV cells. Detection of His-tagged SDPR 
expression was performed by western blotting with three separate antibodies, 
one developed to detect HIS tag and other two to detect SDPR peptide.  
To determine if SDPR can function in another metastatic breast cancer 
cell line, we overexpressed SDPR in MDA-MB-231LM2 (LM2) cells (Fig. 17). 
LM2 cell were developed from MDA-MB-231 cells which were able to colonize   
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Figure 13: Effect of SDPR overexpression on metastasis potential of MIV 
cells. Bioluminescent imaging shows lung metastases on mice 11 weeks after 
tail vein injections of 5x105 control or MIVpQ.SDPR cells.  
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Figure 14: Quantification of SDPR effect on metastasis potential of MIV 
cells. Top graph depicts the percentage of mice that developed lung metastases 
following the tail vein injections with control or MIVpQ.SDPR cells. Lower graph 
shows the number of average lung macrometastases observed per mouse upon 
injection with control or MIVpQ.SDPR cells, p=0.012, npQ=6, npQ.SDPR=5.   
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Figure 15: Effect of SDPR overexpression on metastases potential of MIV 
cells. Hematoxylin and eosin staining was done on sections of extracted lungs. 
Pictures show a sample of H&E stained slides, metastases are highlighted.  
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Figure 16: Effect of SDPR on primary tumor growth. Control (MIVpQ) and 
SDPR overexpressing (MIVpQ.SDPR) cells were injected subcutaneously, and 
tumor growth was tracked using bioluminescent imaging for five weeks, left 
panel. At the end of the experiment tumors were extracted and weighed, right 
panel, n=4.  
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Figure 17: SDPR overexpression in LM2 cells. SDPR expression alters the 
cell morphology of LM2. Western blot assay shows SDPR overexpression in LM2 
cells, left panel. Light microscopy highlights the more epithelial-like morphology 
of SDPR-expressing LM2 cells, right panel.  
mouse lung with a high efficiency (60). The highly efficient metastatic potential of 
LM2 cells represented a stringent test for the ability of SDPR expression to 
counteract metastasis. Similar to our observation with MIV cells, SDPR 
overexpression in LM2 cells led to a 60% reduction in the number of mice with 
metastases and the number of metastatic nodules per mouse significantly 
decreased from 2.8 to 0.8 (Fig. 18 and 19). Overall, these observations suggest 
that SDPR functions as a metastasis suppressor in breast cancer. 
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Figure 18: Effect of SDPR on metastasis potential of LM2 cells. 
Bioluminescent imaging shows lung metastases on mice 35 days after tail vein 
injections with 5x105 control or LM2pQ.SDPR cells.    
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Figure 19: Quantification of SDPR effect on metastasis potential of LM2 
cells. Top graph shows the percentage of mice that developed lung metastases 
following the tail vein injections with control or LM2pQ.SDPR cells. Lower graps 
shows the number of average lung macrometastases observed per mouse upon 
injection with control or LM2pQ.SDPR cells, p=0.006, n=5.  
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SDPR activates the p53 pathway and inhibits ERK and NF-κB pathways 
leading to increased apoptosis 
To understand the mechanism of SDPR action, we performed a number of 
in vitro assays that can assess the changes in major cellular events including 
proliferation, migration and apoptosis. We reasoned that an altered cellular 
function would guide us towards the possible signaling pathways that might be 
affected by SDPR overexpression.  
When we test the effect of SDPR on proliferation rate of MIV cells, we did 
not observe a significant change (Fig. 20).  
Next we investigated the effect of SDPR on migration by performing 
scratch wound healing and Boyden chamber migration assays. We observed that 
SDPR overexpression in MIV cells hindered their ability to migrate (Fig. 21). 
Perhaps most interesting, we found that overexpression of SDPR in MIV 
cells led to a significant increase in the basal apoptosis level from 13.4% to 
17.1% (Fig. 22).  
To determine the molecular basis for the significant increase of apoptosis 
in MIV cells following SDPR overexpression, we examined possible alterations in 
the p53 pathway since p53 is the major player in apoptosis pathway (130, 131). 
Western blot analysis revealed while total p53 levels were decreased in 
MIVpQ.SDPR cells, the protein activity was enhanced as demonstrated by an 
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increase in serine-15 phosphorylation (Fig. 23). Moreover, expression of the 
direct p53 target proteins; PUMA, Bax and Mdm2 (131) were increased in 
MIVpQ.SDPR cells (Fig. 23). We also tested the promoter activity of these genes 
Figure 20: Effect of SDPR overexpression on proliferation rate of MIV cells. 
SDPR expression does not affect cell proliferation. SDPR overexpression in MIV 
cells did not affect cell proliferation as measured by MTS tetrazolium/PMS assay, 
n=3. 
using luciferase reporters and observed that they were significantly more active 
in MIVpQ.SDPR cells, further supporting the notion that SDPR activates the p53 
pathway (Fig. 23). Interestingly, the pro-apoptotic Bcl-2 family proteins Bad, Bid 
and Bim (132) were also expressed more highly in MIVpQ.SDPR cells with a 
concomitant decrease in the anti-apoptotic Bcl-xL protein (Fig. 24). 
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Figure 21: Effect of SDPR overexpression on migration capacity of MIV 
cells. SDPR overexpression in MIV cells led to a slower rate of migration in 
scratch wound healing assay, top panel. Boyden chamber migration assay 
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revealed that fewer MIV cells could migrate through the pores of the membrane 
upon SDPR overexpression.  
Figure 22: Effect of SDPR on apoptotic population of MIV cells. Top panel 
shows Annexin-V and propidium iodide staining which was used to assess the 
basal level of apoptosis in control and MIVpQ.SDPR cells. Lower graph shows 
the quantification of three independent experiments, p=0.015.   
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Figure 23: Effects of SDPR overexpression on p53 pathway in MIV cells. 
Active (phosphorylated p53 at ser 15) and total p53 levels were measured by 
western blot following SDPR overexpression in MIV cells, top left panel. p53 
direct transcriptional targets, PUMA, Bax and Mdm2 showed increased 
expression in MIVpQ.SDPR, right top panel. Luciferase reporter assays showed 
SDPR overexpression led to more active PUMA, Bax and Mdm2 promoters. The 
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p-values for luciferase reporter assays were: pPUMA=0.000003, pBax=0.03, 
pMdm2=0.00006, for all n=3. 
Figure 24: Protein levels of critical apoptosis pathway proteins following 
SDPR overexpression in MIV cells. Pro-apoptotic Bcl2 family members, Bad, 
Bid and Bim and anti-apoptotic Bcl-xL were measure by western blotting in 
control and MIpQ.SDPR cells, left panel. The effect of SDPR overexpression on 
the activity of the pro-survival ERK and NF-κB pathways was evaluated by 
western blotting against phosphorylated Erk and p65 protein levels, respectively, 
mid panel. Caspase 3 protein levels in control and MIVpQ.SDPR cells were 
measured by western blotting after SDPR overexpression.  
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The ERK and NF-κB pathways are major regulators of Bcl2 family 
members, controlling the activities of Bim (133, 134) and Bcl-xL (135, 136), 
respectively. In MIVpQ.SDPR cells, we observed a decrease in ERK and p65 
phosphorylation suggesting that SDPR can restrain the activity of these anti-
apoptotic pathways (Fig. 24). In conjunction with these observations, the levels 
of caspase 3, which is a critical effector caspase whose activity marks a 
commitment to apoptosis in cell (137), were also increased in MIV pQ.SDPR 
cells (Fig. 24).  
Collectively, these observations point towards a shift in the balance of 
apoptotic regulators to favor cell death in the presence of SDPR. 
SDPR impairs growth of MIV cells in 3D culture 
To test the functional consequences of this shift in the apoptotic pathway, 
we interrogated the cells upon loss of adhesion, a situation which metastasis 
competent cells must overcome (2, 6, 71, 138, 139). When grown in 3D cell 
culture, SDPR expression in MIV cells caused a dramatic decrease in cell 
growth, suggesting that SDPR overexpression makes cells more vulnerable to 
loss of adhesion (Fig. 25).  
SDPR effects on apoptotic pathway is not limited to MIV cells 
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The pro-apoptotic effect mediated by SDPR is not limited to MIV cells 
since SDPR significantly increased the basal apoptosis level in LM2 cells as well 
(Fig. 26). Moreover, here too, SDPR overexpression caused dramatic increases  
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Figure 25: Effect of SDPR on growth in 3D cell culture. Control and 
MIVpQ.SDPR cells were grown in 3D cell culture and their growth was monitored 
for 5 days.   
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Figure 26: Effect of SDPR overexpression on apoptosis of LM2 cells. Top 
panel shows Annexin-V and propidium iodide staining which was used to assess 
the basal level of apoptosis in control and LM2pQ.SDPR cells. Lower graph 
shows the quantification of three independent experiments, p=0.0002.  
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in pro-apoptotic Bcl-2 family proteins, accompanied by a decrease in anti-
apoptotic Bcl-xL (Fig. 27). Moreover, perturbations of ERK and NF-κB signaling, 
together with increased caspase 3 levels, were also observed in LM2pQ.SDPR 
cells (Fig. 27).  
Consistent with these observations, SDPR overexpression made LM2 
cells more vulnerable to loss of cell adhesion as demonstrated by growth 
inhibition in 3D culture (Fig.28).  
These results suggest that the impact of SDPR on apoptotic regulators 
was not an MIV cell line specific phenomenon but is potentially applicable to 
broader range of metastatic breast cancer cells. 
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Figure 27: Effect of SDPR overexpression on apoptosis pathway proteins in 
LM2 cells. Effects of SDPR overexpression on the p53 pathway in LM2 cells 
were evaluated by western blotting, top left panel.  The expression of pro-
apoptotic Bcl-2 family members, Bad, Bid, and Bim is increased upon SDPR 
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overexpression, top right panel. These changes were accompanied by a 
decrease in protein levels of anti-apoptotic Bcl-xL protein as determined by 
western blot assays, top right panel. Following SDPR overexpression in LM2 
cells, both Erk and NF-κB pathways were less active as shown by the levels of 
phosphorylated Erk and phosphorylated p65 protein levels, respectively, lower 
right panel. SDPR expression increases total caspase 3 protein levels in LM2 
cells, lower left panel.  
  
85 
 
Figure 28: Effect of SDPR overexpression on growth potential of LM2 cells 
in 3D culture. SDPR blocks cell growth upon loss of adhesion. SDPR 
overexpression hinders the growth of LM2 cells upon loss of adhesion in 3D cell 
culture conditions.  
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SDPR loss is sufficient to inhibit pro-apoptotic signaling in non-metastatic 
NeoT cells 
As we depicted in above experiments, SDPR overexpression caused a 
decrease in the metastatic potential of breast cancer cell lines. SDPR increased 
the activity and levels of pro-apoptotic proteins and decreased those which are 
pro-survival. Based on these observations, we decided to investigate whether 
SDPR lost could cause an opposite result in non-metastatic cells.  Therefore, we 
performed loss-of-function experiments in the non-metastatic precursor of the 
metastatic MIV cells, NeoT.  
SDPR knockdown in NeoT cells (Fig. 29) caused a significant decrease in 
the basal apoptosis level, as we expected (Fig. 30).  
Figure 29: SDPR knockdown in NeoT cells. SDPR was knocked down in non-
metastatic NeoT cells by four different shSDPR constructs. The most complete 
knockdown was achieved by construct #1; hence it was used in all of the 
subsequent experiments performed.   
Actin 
Sdpr 
shGFP #1 #2 #3 #4 
shSDPR 
NeoT 
87 
 
Figure 30: Loss of SDPR increases cell survival. Effect of SDPR knockdown 
on basal apoptotic population in the non-metastatic NeoT cells was measured by 
annexin-v staining and propidium iodide staining, top panel. Effect of SDPR 
knockdown on NeoT cells were quantified, p= 0.007, n=3.  
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The decrease in the apoptotic population of NeoT cells following SDPR 
knockdown was consistent with an observed decreased in the levels of 
phosphorylated p53, as well as direct p53 target proteins such as PUMA and 
Bax, (Fig. 31).  
Moreover, pro-apoptotic Bcl-2 family members, Bad and Bim, as well as 
caspase-3 levels were all decreased following SDPR knockdown, while ERK 
phosphorylation was increased, suggesting that the balance of apoptotic pathway 
regulators was tipped towards survival upon SDPR knockdown (Fig. 32).  
Furthermore, NeoTshSDPR cells exhibited enhanced growth potential in 
3D cell culture compared to control cells (Fig. 33).  
Overall, these observations support the notion that loss of SDPR 
expression can be sufficient to affect critical pro- and anti-apoptotic regulators 
and, hence, strengthen our hypothesis that SDPR functions as a metastasis 
suppressor in breast cancer. 
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Figure 31: Effects of SDPR knockdown on the p53 pathway in NeoT. p53 
activity was evaluated by western blotting, top panel, and luciferase reporter 
assays, lower panel. The p-values for luciferase reporter assays were: 
pPUMA=0.0014, pBax= 0.0016  
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Figure 32: Effect of SDPR knockdown on apoptosis pathway proteins in 
NeoT cells. Protein levels of pro-apoptotic Bcl2 family members, Bad, Bid and 
Bim, and anti-apoptotic Bcl-xL were measured by western blotting in control and 
NeoTshSDPR, left panel. Activity of ERK and NF-κB pathways were assessed by 
western blotting following SDPR knockdown in NeoT cells, mid panel. Caspase 3 
protein levels in control and NeoTshSDPR cells were measured by western 
blotting, right panel.  
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Figure 33: Effect of SDPR knockdown on growth in 3D culture. Control and 
NeoTshSDPR cells were grown in 3D cell culture, p=0.0211, n=3.  
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SDPR down-regulation is not limited to breast cancer and is observed in a 
wide variety of cancers 
The meta-analysis we have carried out using the Oncomine™ database 
revealed that SDPR was repressed in breast cancer, as shown by 12 separate 
studies (Fig. 34.1 and 34.2). We wanted to further investigate SDPR status in 
breast cancer by analyzing its protein expression. We utilized another online 
software tool available, the Human Protein Atlas for this purpose (104, 105). The 
Human Protein Atlas includes a comprehensive antibody based proteomics 
analysis of human tumors. Our meta-analysis showed that SDPR protein was not 
detectable in breast tumors whereas in normal breast tissue, the SDPR protein 
was detectable (Fig. 35). These observations indicated that SDPR repression in 
breast cancer was evident at both mRNA and protein level.  
Moreover, interestingly, SDPR loss was not limited to breast cancer, as 
tumor samples from bladder, colorectal, lung, prostate, ovarian cancers and even 
sarcoma showed loss of SDPR expression in the Oncomine™ database analysis 
(Table 5). Taken together with studies that showed down-regulation of SDPR in 
kidney and prostate cancers (119, 121), this analysis suggested that SDPR may 
have broader clinical relevance beyond breast cancer. 
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Figure 34.1: Expression levels of SDPR in clinical samples. 
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Figure 34.2: Expression levels of SDPR in clinical samples. Twelve gene 
expression profiling studies from the Oncomine™ database showed the SDPR 
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expression in breast cancer is significantly repressed. IDBC: Invasive Ductal 
Breast Carcinoma, IBC: Invasive Breast Carcinoma, ILBC: Invasive Lobular 
Breast Carcinoma, MBC: Mucinous Breast Carcinoma, TBC: Tubular Breast 
Carcinoma, MeBC: Medullary Breast Carcinoma, BC: Breast Carcinoma. p-
values are 5.95E-07, 3.70E-33, 2.32E-14, 2.68E-55, 1.16E-17, 4.64E-81, 6.55E-
64, 3.28E-56, 3.45E-63, 6.27E-90, 1.73E-31 and 1.35E-13 respectively for each 
study.  
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Figure 35: SDPR protein levels in breast cancer. (a) Myoepithelial cells in 
normal breast tissue are positive for SDPR protein. On the other hand, ductal 
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carcinoma samples from eight patients (b) and lobular carcinoma samples from 
three patients (c) are all negative for SDPR protein staining.  
 
Table 5: Summary of Oncomine™ analysis for SDPR. Oncomine™ database 
analysis showed that SDPR was significantly suppressed in a wide variety of 
cancer types in 27 separate studies.  
Type Number of studies that 
showed significant 
downregulation of SDPR 
Number of studies that 
showed significant 
upregulation of SDPR 
Bladder Cancer 1 0 
Breast Cancer 12 0 
Colorectal Cancer 2 0 
Lung Cancer 5 0 
Pancreatic Cancer 1 0 
Ovarian Cancer 1 0 
Other 1 0 
Sarcoma 4 0 
Brain and CNS 
cancer 
0 1 
Total 27 1 
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SDPR is suppressed epigenetically during metastatic progression 
Previous studies showed that the metastasis suppressors CDH1 and 
CASP-8 are silenced due to promoter DNA hypermethylation (44, 90). Moreover, 
expression levels of the metastasis suppressors DRG1 and NME1 increase 
dramatically upon 5’-aza-deoxycytidine treatment (91, 92). These findings 
suggest that DNA methylation is an important mechanism for regulation of 
metastasis suppressor genes.  
Therefore, we investigated the effect of 5’-aza-deoxycytidine treatment on 
SDPR expression in MIV cells. Indeed, the treatment increased mRNA levels of 
SDPR more than 3 fold and restored it to a level comparable to what  is observed 
in non-metastatic NeoT cells (Fig. 36). We analyzed the promoter region (-1000 
to +1000) of SDPR using the MethPrimer online software tool. The GC 
percentage graph plotted by MethPrimer showed CpG sites, estimated CpG 
islands and provided methylation specific primers targeting CpG sites at +300 
and +320 (Fig. 37). Quantitative methylation specific PCR (Q-MSP) analysis 
revealed that the SDPR promoter region is significantly hypermethylated in 
metastatic MIV cells compared non-metastatic NeoT cells which was, expectedly, 
inversely correlated with SDPR levels (Fig. 37). Interestingly, significant 
hypermethylation of CpG sites at +300 and +320 was observed in the majority of 
metastatic breast cancer cell lines we tested compared to non-metastatic lines 
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(Fig. 38). These findings suggest that, similar to other metastasis suppressors, 
SDPR is epigenetically repressed due to DNA hypermethylation in breast cancer 
and hence, provide a possible explanation why SDPR eluded identification by 
genomic efforts (44, 45, 140).  
 
Figure 36: Effect of 5-aza treatment on SDPR expression in MIV cells. 
Relative expression levels of SDPR mRNA in NeoT and MIV cells measured by 
quantitative RT-PCR, p=0.0127, n=3. Effect of 5-aza-2'-deoxycytidine treatment 
on SDPR mRNA levels in MIV cells, p= 0.02, n=3.   
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Figure 37: Methylation status of SDPR promoter region in model cell lines. 
Analysis of -1000 to +1000 region of SDPR transcription start site for CpG sites 
on MethPrimer online tool. Methylation specific quantitative PCR reveals the 
DNA methylation percentages of SDPR promoter region in NeoT and MIV cell 
lines, p=0.0116, n=3. SDPR levels are depicted below the graph.   
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Figure 38: Percentage of DNA methylation on the SDPR promoter region 
across non-metastatic and metastatic breast cancer cell lines. MSP 
revealed the significant difference in methylation levels of SDPR promoter which 
inversely correlated with SDPR protein levels between non-metastatic and 
metastatic cell lines, p=0.0007, nnon-met=3, nmet=7. Western blot analysis depicted 
the SDPR protein levels across the cell lines, lower panel.  
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DISCUSSION 
In this chapter, we presented data that functionally and mechanistically 
supports the discovery of SDPR as a bona fide metastasis suppressor. Studies 
on SDPR function have been limited to its role as a regulator of caveolae 
formation (116), and its functional involvement in cancer has not been reported. 
SDPR is localized to 2q32-33, a region with a significant level of loss of 
heterozygosity (LOH) and a high degree of recurrence in breast cancer (123, 
124). Interestingly, CASP8, which is subject to truncating mutations in breast 
cancer as determined by exome sequencing analysis, and implicated as a 
metastasis suppressor, also localizes to 2q33 (43, 95).  
Our results indicate that SDPR is capable of inhibiting the metastatic 
growth of cancer cells.  Mechanistically, SDPR simultaneously activates the p53 
pathway and inhibits ERK and NF-κB signaling, which primes would-be 
metastatic cells for apoptosis following loss of cell adhesion.  Conversely, 
knockdown of SDPR in non-metastatic cells promoted cell survival, indicating 
that SDPR is both sufficient and necessary in promoting cell death in this context.  
Additionally, SDPR expression is dramatically decreased in human breast 
tumors, and patients with higher levels of SDPR expression have a significantly 
better prognosis, supporting the clinical relevance of this novel metastasis 
suppressor. Moreover, SDPR expression can be restored by 5-aza-2'-
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deoxycytidine treatment and it is suppressed due to DNA methylation during 
metastasis.  
  
104 
 
FUTURE DIRECTIONS 
The data we have presented supports the role of SDPR as a novel 
metastasis suppressor gene in breast cancer. However to strengthen our findings 
and understand the more precisely the molecular mechanism of SDPR action 
under normal and disease states requires more studies. Similarly, the regulation 
of SDPR deserves more detailed investigation. 
Our in vitro experiments indicate that SDPR can affect the apoptosis 
pathway by activating p53 and inhibiting Erk and NF-κB signaling. We plan to test 
the functional relevance of this using the in vivo lung colonization assay. This 
experiment will involve injection of control and SDPR overexpressing metastatic 
cancer cells into tail vein of mice. Cell survival after 48 hours of injection will be 
assessed by staining lung sections with human specific antibodies such as those 
developed against human vimentin. We hypothesize that SDPR overexpression 
will sensitize cells for apoptosis. Therefore, we expect to observe a reduction in 
the number of SDPR overexpressing cancer cells compared to control. This 
would indicate that SDPR suppression gives metastatic cancer cells an 
advantage during later stages of metastatic cascade i.e. extravasation and 
colonization. Since there will be more surviving cells stuck in capillaries of distant 
tissues following intravasation, this increases the chance for a metastasis to 
develop. This experiment will provide evidence that the effect of SDPR on 
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apoptosis we observed in vitro may have consequences in vivo, during 
metastasis. 
We showed the metastasis suppressor function of SDPR by performing 
tail vein injections. This setup allowed us to test the later stages of the metastatic 
cascade, that is, extravasation and colonization, but it cannot assess the effect of 
SDPR on earlier stage of intravasation. Therefore, we plan to test effect of SDPR 
on mammary tumor dissemination to distant organs by orthotopic breast cancer 
inoculation. Metastatic breast cancer cells with or without SDPR overexpression 
will be injected to mammary gland of mice. Following primary tumor formation, 
we will monitor the intravasation rate by testing the blood of the mice with PCR 
using human specific primers against housekeeping genes. When the primary 
tumors reach a certain size, the mammary glands and primary tumors will be 
cleared by mastectomy. Bioluminescent imaging will be performed to monitor 
metastatic growths that may occur in lungs, bones, liver and brain of mice. At the 
end of experiment, histology will be done to assess the outgrowth of any 
metastatic lesions. Using this experimental setup, we can expect to observe the 
effect of SDPR on the entire metastatic cascade. 
We also plan to demonstrate the effect of SDPR on metastasis by using a 
third metastatic breast cancer cell line model, SUM159 which will strengthen the 
notion that the metastasis suppressor function of SDPR is not cell line specific. 
Our preliminary results indicated that SDPR can hinder metastatic potential of 
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SUM159 cells since in the control group, 50% of mice developed metastasis 
whereas in the group injected with SDPR overexpressing cells, none of the mice 
developed detectable metastases (Fig. 39). Therefore, we find our preliminary 
experiment worthy of expansion.  
Figure 39: Effect of SDPR overexpression on metastatic potential of 
SUM159 cells. Bioluminescent imaging performed to assess SDPR effect on 
SUM159 cells’ metastatic potential.  
We also plan to test the effect of SDPR on metastasis by using transgenic 
mouse experiments. We will cross SDPR+/- heterozygous and SDPR-/- complete 
knockout mice, which was already generated (115), with an oncomouse such as 
mouse strain, FVB.Cg-Tg(MMTV-vHaras)SH1Led/J (141). Oncomouse strain 
spontaneously develops mammary tumors that rarely metastasize to lung and 
liver. Following the crosses, we expect that complete SDPR knockout mouse will 
experience an increase in metastatic nodules that is formed. For mouse with 
SUM159 
pQ 
SUM159 
pQSDPR 
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SDPR+/-, we expect an intermediate level of metastases formation compared to 
control and SDPR-/- mouse. We also may observe loss of heterozygosity in 
formed metastatic nodules due to a possible advantage that can be gained by a 
cancer cell following complete loss of SDPR expression. This transgenic mouse 
experiments can let us prove the critical role SDPR play during breast cancer 
progression. 
To broaden our understanding on mechanism of SDPR action we want to 
investigate the molecular interacting partners of SDPR. Since there is evidence 
regarding the effect of SDPR on apoptotic pathways, we hypothesize that SDPR 
might interact with molecules in p53, Erk or NF-κB pathway. By performing co-
immunoprecipitation assays we expect to show a potential SDPR interaction with 
candidate proteins that may play a role in apoptosis and survival signaling. 
Additionally, as an unbiased method, immunoprecipitation of the SDPR protein 
could be followed by mass spectrometry analysis which can reveal interacting 
protein partners of SDPR and present additional insight into mechanism of SDPR 
function. It is noteworthy that in our breast cancer model cell lines, p53 is wild 
type in MIV cells but mutated in LM2 cells indicating metastasis suppressor 
function of SDPR can be independent of p53 status. In our immunoprecipitation 
assays we will control for this fact by performing our experiments both in p53 wild 
type and p53 mutant breast cancer cell lines since SDPR may interact with a 
different set of protein partners.   
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 Interrogation of a larger breast cancer patient cohort regarding SDPR 
mRNA and protein levels will strengthen our meta-analysis findings. Especially, 
providing evidence that would associate SDPR levels with the prognosis of the 
disease could lead to identification of SDPR as a biological marker.   
 Another aspect of our study has been trying to understand SDPR 
regulation during breast cancer progression. We have provided data that 
indicated DNA methylation plays a significant role in regulating SDPR levels. We 
plan to perform DNA methylation analysis on the identified CpG sites at +300 and 
+320 of SDPR in clinical samples. This will help to establish the clinical relevance 
of these DNA methylation sites on the SDPR promoter region. 
 Moreover, we want to clone the promoter region of SDPR in to a luciferase 
reporter vector. We aim to identifying possible candidate drugs that can activate 
transcription of SDPR using a drug screening assay. In the long term, this may 
guide us in the development of a therapeutic approach to increase the 
expression of SDPR to activate its metastasis suppressor function in patients.  
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CONCLUSIONS 
Metastasis is the major cause of cancer related deaths. That is why 
understanding of the whole metastatic cascade in detail is vital for our effort 
against the disease. Very early on in the study of cancer, researchers realized 
that not all cancer patients develop metastasis and, notably, some patients with 
disseminated cancer cells failed to develop clinical manifestations (16, 142). 
These observations strongly indicate that there exist natural barriers blocking 
metastasis that a cancer cell must overcome. To date, mutational analysis of 
metastatic lesions has not revealed significant genetic changes in metastatic 
lesions versus primary tumors. There are a few possible explanations for this 
(93): One explanation can be the difficulty in identifying epigenetic changes 
occurring during metastasis. Another explanation may be that we simply did not 
study metastatic lesions sufficiently to unravel mutations in a heterogeneous 
population of cells. Finally, there might be no metastasis specific mutations at all. 
What is certain however, is that only a fraction of malignant cells can metastasize 
and in some cases only after a long period of dormancy. Once we understand 
the molecular players and their functions during metastasis, we may cope with 
the disease.    
We used a cell line based model system that shares the same genetic 
background in order to identify novel genes that may play a critical role in 
metastasis of breast cancer. The strength of this model lies on its development 
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from a single parental cell line, MCF10A. It is established that MII cells behave as 
carcinoma in situ, MIII cells as carcinoma and MIV cells as metastatic carcinoma. 
By analyzing gene expression profiles of these three cell lines, we identified the 
genes that were specifically down-regulated in metastatic MIV cells. Among 
these differentially expressed genes, we expected many would be “passenger 
genes”, that were down-regulated accidently and gave no advantage to a cancer 
cell during breast cancer progression. Therefore to narrow down the number to 
possible “driver genes”, that are responsible for breast cancer progression, we 
performed meta-analysis on OncomineTM and Kaplan Meier Plotter.  SDPR was 
the most promising candidate metastasis suppressor gene from these studies. 
SDPR was shown to significantly down-regulated by ~10 fold in metastatic MIV 
cells compared to non-metastatic parental cell lines.  This significant suppression 
was captured in studies on OncomineTM database using clinical samples. 
Moreover, the possible effect of SDPR on clinical outcome was suggested by a 
significant association between higher expression of SDPR and longer relapse-
free survival of breast cancer patients.  
SDPR is a known regulator of caveolae formation (116). Although, its 
location at 2q32-33 points to its potential involvement in breast cancer (123) 
there have been no reports describing a role for SDPR in the initiation of cancer 
or in metastasis. The first step we took to elucidate the functional role of SDPR in 
breast cancer metastasis was the reintroduction of SDPR expression in 
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metastatic MIV cells. We hypothesized that SDPR expression in MIV cells would 
hinder their metastatic potential.  Indeed, upon stable SDPR overexpression, MIV 
cells showed a significant decrease in metastatic potential as observed in in vivo 
metastasis assays. To show that the role of SDPR as a metastasis suppressor is 
not limited to MIV cells, we tested our hypothesis in metastatic LM2 cells. We 
observed that SDPR exhibited a metastasis suppressor function in LM2 cells as it 
did in MIV. This observation supports the idea that the function of SDPR as a 
metastasis suppressor is not cell line-specific.  
Next we sought to determine the mechanism of SDPR action by 
performing experiments in which we tested important cellular functions such as 
apoptosis. When we investigated the percentage of MIV cells undergoing 
apoptosis following SDPR overexpression, we observed a significant increase. 
This was an interesting observation in the light of the fact that a malignant cell 
must suppress apoptosis to successfully complete the metastatic cascade. The 
vast majority of intravasating cancer cells undergo apoptosis due to loss of cell 
adhesion during transit in the circulation. Therefore, even a seemingly low but 
significant percent increase in the population for MIVpQ.SDPR cells undergoing 
apoptosis may put them at a critical disadvantage compared to control cells. This 
was particularly apparent in 3D cell culture experiments where cells needed to 
grow without solid attachments. The increase in the apoptotic population and 
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concurrent inhibition of growth in 3D cell culture was also observed in LM2 cells, 
indicating that these effects of SDPR were not specific to the MIV cell line.  
We identified that the activation of pro-apoptotic and inhibition of pro-
survival signaling was the potential underlying molecular mechanism for SDPR 
function in both MIV and LM2 cell lines. We observed activation of the p53 
pathway and increased expression of pro-apoptotic Bcl-2 family proteins 
following SDPR overexpression. These data paralleled the results indicating the 
inhibition of pro-survival ERK and NF-κB signaling upon SDPR overexpression. 
Moreover, we performed knock down experiments of SDPR in the non-metastatic 
parental cell line of MIV, NeoT. We hypothesized that the loss of SDPR 
expression in NeoT cells would lead to an increase in survival. In support of this 
hypothesis, NeoTshSDPR cells showed a significantly smaller population of 
apoptotic cells compared to control. Furthermore, NeoTshSDPR cells grew at a 
faster rate in 3D cell culture. Overall, this data suggests that SDPR alters the 
balance of the apoptotic pathway in favor of cell death (Fig. 40).  
We sought to gain a better understanding of the importance of SDPR from 
a clinical perspective. Data from Kaplan Meier Plotter suggested that higher 
SDPR expression is significantly associated with longer relapse free survival. 
Additionally, meta-analysis using the Oncomine™ database revealed SDPR was 
suppressed not only in breast cancer but also in other types of cancer including 
bladder, colorectal, lung, prostate and sarcoma. This observation suggests that 
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the function of SDPR as a gatekeeper of cancer progression may not be limited 
to breast cancer.  
Figure 40: Working model for the effect of SDPR on apoptosis pathway. Our 
findings indicated that SDPR directly or indirectly activated p53 pathway and 
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inhibited pro-survival Erk and NF-κB pathway. These changes tipped the balance 
of apoptotic pathway towards cell death and presented and possible molecular 
explanation for SDPR mechanism of action.  
In our study, we also investigated the mechanism of SDPR suppression in 
metastatic breast cancer. Epigenetic regulation, especially DNA methylation has 
been shown to play a critical role during cancer progression. Q-MSP results 
indicated that SDPR was suppressed by DNA methylation in MIV cells and 
blocking methylation using 5’-aza-deoxycytidine restored SDPR levels 
comparable to that which was observed in the non-metastatic parental cell line, 
NeoT. We also observed that methylation of CpG sites at +300 and +320 
occurred at significantly higher levels in metastatic breast cancer cell lines 
compared to the non-metastatic ones. These findings suggest that DNA 
methylation is a key mechanism for SDPR suppression in breast cancer 
progression.  
Current literature can mostly shed light on SDPR function regarding its 
role in caveolae formation and regulation. Possible function of SDPR in cancer 
progression has been largely limited to expression level analysis comparing 
normal tissues to matching cancer samples. Our work suggests a critical function 
for SDPR in breast cancer progression. Therefore, it has the potential to add 
another dimension to caveolae research related to cancer field. 
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In conclusion, our observations support the hypothesis that SDPR is a 
metastasis suppressor, affecting multiple pro- and anti-apoptotic pathways in 
breast cancer. Therefore, it is plausible that disseminating cancer cells with 
compromised SDPR function have a selective advantage during metastatic 
colonization. Importantly, restoring SDPR expression by manipulating epigenetic 
mechanisms may present a strategy to block breast cancer metastasis.  
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